Compounds for treatment of infectious and immune system disorders and methods for their use

Abstract

The present invention provides polypeptides comprising an immunogenic epitope of a M. vaccae protein, polynucleotides encoding such polypeptides, and fusion proteins comprising at least one such polypeptide, together with DNA constructs comprising at least one inventive polynucleotide. Compositions comprising such polypeptides, polynucleotides, fusion proteins and/or DNA constructs may be employed in the treatment of infectious diseases and immune disorders.

Description

TECHNICAL FIELD

The present invention relates generally to the detection, treatment and prevention of infectious diseases. In particular, the invention is related to compounds comprising immunogenic epitopes isolated from Mycobacterium vaccae , and the use of such compounds in vaccination or immunotherapy against infectious disease, including mycobacterial infections such as infection with Mycobacterium tuberculosis or Mycobacterium avium , and in certain treatments for immune disorders and cancer.

BACKGROUND OF THE INVENTION

The present invention relates generally to the treatment and prevention of infectious diseases, and to the treatment of certain immune disorders and cancers. In particular, the invention is related to compounds and methods for the treatment and prevention of mycobacterial infections including infection with Mycobacterium tuberculosis or Mycobacterium avium.

Tuberculosis is a chronic, infectious disease that is caused by infection with Mycobacterium tuberculosis ( M. tuberculosis ). It is a major disease in developing countries, as well as an increasing problem in developed areas of the world, with about 8 million new cases and 3 million deaths each year. Although the infection may be asymptomatic for a considerable period of time, the disease is most commonly manifested as a chronic inflammation of the lungs, resulting in fever and respiratory symptoms. If left untreated, significant morbidity and death may result.

Although tuberculosis can generally be controlled using extended antibiotic therapy, such treatment is not sufficient to prevent the spread of the disease. Infected individuals may be asymptomatic, but contagious, for some time. In addition, although compliance with the treatment regimen is critical, patient behaviour is difficult to monitor. Some patients do not complete the course of treatment, which can lead to ineffective treatment and the development of drug resistant mycobacteria.

Inhibiting the spread of tuberculosis requires effective vaccination and accurate, early diagnosis of the disease. Currently, vaccination with live bacteria is the most efficient method for inducing protective immunity. The most common mycobacterium employed for this purpose is Bacillus Calmette-Guerin (BCG), an avirulent strain of Mycobacterium bovis . However, the safety and efficacy of BCG is a source of controversy and some countries, such as the United States of America, do not vaccinate the general public. Diagnosis of M. tuberculosis infection is commonly achieved using a skin test, which involves intradermal exposure to tuberculin PPD (protein-purified derivative). Antigen-specific T cell responses result in measurable induration at the injection site by 48-72 hours after injection, thereby indicating exposure to mycobacterial antigens. Sensitivity and specificity have, however, been a problem with this test, and individuals vaccinated with BCG cannot be distinguished from infected individuals.

A less well-known mycobacterium that has been used for immunotherapy for tuberculosis, and also leprosy, is Mycobacterium vaccae , which is non-pathogenic in humans. However, there is less information on the efficacy of M. vaccae compared with BCG, and it has not been used widely to vaccinate the general public. M. bovis BCG and M. vaccae are believed to contain antigenic compounds that are recognised by the immune system of individuals exposed to infection with M. tuberculosis.

Several patents and other publications disclose treatment of various conditions by administering mycobacteria, including M. vaccae , or certain mycobacterial fractions. International Patent Publication WO 91/02542 discloses treatment of chronic inflammatory disorders in which a patient demonstrates an abnormally high release of IL-6 and/or TNF or in which the patient's IgG shows an abnormally high proportion of agalactosyl IgG. Among the disorders mentioned in this publication are psoriasis, rheumatoid arthritis, mycobacterial disease, Crohn's disease, primary biliary cirrhosis, sarcoidosis, ulcerative colitis, systemic lupus erythematosus, multiple sclerosis, Guillain-Barre syndrome, primary diabetes mellitus, and some aspects of graft rejection. The therapeutic agent preferably comprises autoclaved M. vaccae administered by injection in a single dose.

U.S. Pat. No. 4,716,038 discloses diagnosis of, vaccination against and treatment of autoimmune diseases of various types, including arthritic diseases, by administering mycobacteria, including M. vaccae . U.S. Pat. No. 4,724,144 discloses an immunotherapeutic agent comprising antigenic material derived from M. vaccae for treatment of mycobacterial diseases, especially tuberculosis and leprosy, and as an adjuvant to chemotherapy. International Patent Publication WO 91/01751 discloses the use of antigenic and/or immunoregulatory material from M. vaccae as an immunoprophylactic to delay and/or prevent the onset of AIDS. International Patent Publication WO 94/06466 discloses the use of antigenic and/or immunoregulatory material derived from M. vaccae for therapy of HIV infection, with or without AIDS and with or without associated tuberculosis.

Traditional vaccines contain the disease-causing organism (or a component thereof) in either attenuated or killed form. As an alternative approach to traditional vaccines, DNA vaccines have been developed for diseases as diverse as AIDS, influenza, cancer and malaria. Clinical trials of DNA vaccines are in progress for a number of these diseases. A typical DNA vaccine consists of DNA encoding an antigen cloned in a non-active plasmid carrier. Expression of the antigen encoded by the vaccine DNA is usually under control of a strong promoter, such as human β-actin, Rous sarcoma virus (RSV) or CMV promoter (Ramsay AJ, et al. Immunology and Cell Biology 75:360-363, 1997). The first experimental evidence that DNA vaccines were able to induce the desired immune response was produced by Tang et al. (Tang D-C, et al. Nature 356:152-154, 1992). In these experiments, mice inoculated with plasmids containing the gene encoding for human growth hormone developed specific primary antibody responses.,

Immune responses to two DNA vaccines containing genes from M. tuberculosis have been evaluated in animal models. The first vaccine contained the gene coding for the GroEL stress protein (65 kDa protein; Tascon RE, et al. Nature Med . 2:888-892, 1996). Mice injected with this DNA vaccine were protected at a level equivalent to mice receiving the traditional BCG vaccine. The second DNA vaccine against M. tuberculosis contained DNA encoding an antigen from the antigen 85 complex and similar results to the study by Tang et al. were obtained (Huygen K, et al. Nature Med . 2:893-898, 1996). U.S. Pat. No. 5,736,524 discloses vaccination of domestic mammals or livestock against infection by M. tuberculosis or M. bovis by administering a polynucleotide tuberculosis vaccine comprising the M. tuberculosis antigen 85 gene operably linked to transcription regulatory elements.

The first human DNA vaccine trial was reported recently (Wang R, et al. Science 282:476-80, 1998). In this trial, an antigen from Plasmodium falciparum , the causative agent of malaria, was injected into healthy volunteers. The desired immune response was elicited, as demonstrated by the presence of cytotoxic T (CD8 + ) lymphocytes (CTL), suggesting that the immune system would be able to clear parasites from infected patients. Safety and immunogenicity of a human DNA vaccine against HIV-1 infection was determined in a trial performed by McGregor et al. ( J. Infect. Dis . 178:92-100, 1998). Experimental data from other DNA vaccine experiments has also suggested that antibodies, MHC class 1-restricted CD8 + CTL and class II-restricted CD4 + helper T cells are produced following injection with DNA vaccines (Ramsay, AJ et al. Immunology and Cell Biology 75:360-363, 1997).

DNA vaccines have distinct advantages over more traditional vaccines containing killed or attenuated organisms. DNA vaccination induces immune responses that are long-lived and therefore only a single inoculation may be required. DNA encoding a number of antigens may be incorporated into a single plasmid thereby providing protection against a number of diseases. The technology for DNA vaccine production is relatively simple and the same technology can be used to produce all vaccines, with a resulting cheaper production cost. Delivery of efficacious traditional vaccines to the patient are dependent on maintaining an unbroken “cold chain” from manufacturer to clinic. DNA vaccines produced in solution or in dried form are not sensitive to storage conditions.

One limitation of DNA vaccines is that the immune response is induced against protein components of the pathogen, only. Some traditional vaccines are aimed at inducing an immune response against the polysaccharide outer membrane of pathogens, for example the pneumococcal vaccine against bacterial pneumonia. These molecules are not yet targeted by DNA vaccines.

Recently, alternative ways of constructing and applying DNA vaccines have been developed. In one of the techniques, called Somatic Transgene Imunisation (STI), the plasmid DNA carrying an immunoglobulin heavy chain gene under the control of tissue-specific regulatory elements was inoculated directly into the spleen of mice, with subsequent expression of the antigen on the surface of B-cells (Xiong S, et al. Proc. Natl. Acad. Sci. USA 94:6352-6357, 1997). These B cells produced antibodies against the expressed antigen, leading to an immune response. Subsequent studies showed that STI induced persistent immunologic memory for up to 2 years (Gerloni M, et al. Vaccine (2-3):293-297, 1998).

Expression Library Immunization (ELI) is another technique employing DNA vaccines (Barry MA, et al. Nature 377:632-635, 1995). In this technique, fragments of the complete genome of a pathogen are cloned into a vector and used as vaccine. Selection of protective antigen(s), particularly those inducing CTL, is done by screening and re-screening pools of clones until single clones can be identified. The polynucleotide or polypeptide identified may then be incorporated into a proven delivery system.

Progress on the development of an epitope-based vaccine for the treatment and prevention of HIV infection by scientists at Epimmune Inc. (San Diego, Calif.), has been published recently (Ishioka GY, et al., Journal of Immunology 162:3915-3925, 1999).

There remains a need in the art for effective compounds and methods for preventing and treating infectious disorders, such as tuberculosis and other mycobacterial infections in humans and in domestic mammals or livestock, and for the treatment of certain immune system-related disorders.

SUMMARY OF THE INVENTION

Briefly stated, the present invention provides compounds and methods for the prevention and treatment of infectious diseases, such as mycobacterial infections, and for the treatment of immune disorders and cancers.

In a first aspect, isolated polynucleotides are provided that are derived from the M. vaccae genome. These polynucleotides encode polypeptide epitopes selected on the basis of their immunogenic properties as illustrated by results from a number of immunological assays. In specific embodiments, the inventive polynucleotides comprise a sequence selected from the group consisting of: (a) sequences provided in SEQ ID NO: 8-21; (b) sequences having at least 50%, 75% or 90% identical residues to a sequence of SEQ ID NO: 8-21 as determined using the computer algorithm BLASTN; and (c) compliments of the sequences of (a) and (b).

In a second aspect, the invention provides isolated polypeptides comprising an immunogenic epitope of a M. vaccae antigen. In specific embodiments, the inventive polypeptides comprise a sequence selected from the group consisting of: (a) sequences provided in SEQ ID NO: 61-77; and (b) sequences having at least 50%, 75% or 90% identical residues to a sequence of SEQ ID NO: 61-77 as determined using the computer algorithm FASTX.

DNA constructs comprising at least one of the inventive polynucleotides, and host cells transformed or transfected with such DNA constructs are also provided.

In another aspect, the present invention provides fusion proteins comprising at least one polypeptide of the present invention.

Within other aspects, the present invention provides pharmaceutical compositions that comprise at least one of the inventive polypeptides, polynucleotides, fusion proteins or DNA constructs, and a physiologically acceptable carrier. The invention also provides vaccines comprising at least one of the above polypeptides, polynucleotides, fusion proteins or DNA constructs and a non-specific immune response amplifier.

In yet another aspect, methods are provided for enhancing an immune response in a patient, comprising administering to a patient an effective amount of one or more of the above pharmaceutical compositions and/or vaccines. In one embodiment, the immune response is a Th1 response.

In further aspects of this invention, methods are provided for the treatment of a disorder in a patient, comprising administering to the patient a pharmaceutical composition or vaccine of the present invention. In certain embodiments, the disorder is selected from the group consisting of immune disorders, infectious diseases and cancer.

These and other aspects of the present invention will become apparent upon reference to the following detailed description. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-F illustrate the induction of protective immunity, measured as a decrease in M. tuberculosis CFU in lung and spleen homogenates of BALB/cByJ mice, by vaccination with M. bovis BCG ( FIGS. 1A and D , respectively), with ME/D DNA ( FIGS. 1B and E , respectively), or with rME/D ( FIGS. 1C and F , respectively).

FIGS. 2A-D show the proliferative responses of lymph node cells from BALB/cByJ mice immunized subcutaneously with rME/A (FIG. 2 A), rME/B ( FIG. 2B ) or rME/D (FIG. 2 C). Control mice were immunized with PBS (FIG. 2 D).

FIGS. 3A-D illustrate IFN-γ secretion by lymph node cells from BALB/cByJ mice immunized subcutaneously with recombinant multi-epitope constructs rME/A (FIG. 3 A), rME/B ( FIG. 3B ) or rME/D (FIG. 3 C). Control mice were immunized with PBS (FIG. 3 D).

FIGS. 4A-B demonstrates the proliferative responses of lymph node cells from BALB/cByJ mice immunized with rME/A, rME/D or ME/D DNA by three different routes of immunization. The proliferative response of lymph node cells from control mice immunized with PBS is shown in FIG. 4 B.

FIGS. 5A-B demonstrates the level of IFN-γ secretion by lymph node cells from BALB/cByJ mice immunized with rME/A, rME/D or ME/D DNA by three different routes of immunization. The level of IFN-γ secretion by control mice immunized with PBS is shown in FIG. 5 B.

FIGS. 6A-B show the contribution of single epitopes to the proliferative responses of lymph node cells from BALB/cByJ mice immunized with rME/A, rME/D or ME/D DNA by three different routes of immunization. The proliferative response of lymph node cells from control mice immunized with PBS is shown in FIG. 6 B.

FIGS. 7A-B demonstrates contribution of single epitopes to the level of IFN-γ secretion by lymph node cells from BALB/cByJ mice immunized with rME/A, rME/D or ME/D DNA by three different routes of immunization. The level of IFN-γ secretion by control mice immunized with PBS is shown in FIG. 7 B.

FIGS. 8A-B illustrate the titre and subclass of anti-ME antibodies in the serum of mice immunized with ME/D DNA that reacted with rME/A and rME/D in vitro. The titres of IgG1 antibodies are shown in FIG. 8A , with the titre of IgG2a antibodies being shown in FIG. 8 B.

FIGS. 9A-C show the IFN-γ secretion by memory splenocytes from BALB/cByJ mice immunized with recombinant single epitopes ( FIG. 9B ) or rME/D (FIG. 9 C). IFN-γ secretion by splenocytes after stimulation with controls is shown in FIG. 9 A.

FIGS. 10A-B demonstrate the IFN-γ secretion ( FIG. 10A ) and proliferative response ( FIG. 10B ) by human PBMC after stimulation in vitro with rME/A, rME/B or rME/D.

FIGS. 11A-B demonstrate the IFN-γ secretion ( FIG. 11A ) and proliferative response ( FIG. 11B ) by human PBMC after stimulation in vitro with eight recombinant single epitopes.

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed to compositions and methods for preventing and treating disorders including infectious diseases and certain immune disorders and cancers. Examples of such disorders include, but are not limited to, mycobacterial infections, including M. tuberculosis and M. avium infections; and disorders in which the stimulation of a Th1 immune response is beneficial, including (but not limited to) psoriasis and allergic rhinitis.

Certain pathogens, such as M. tuberculosis , as well as certain cancers, are effectively contained by an immune attack directed by CD4 + T cells, known as cell-mediated immunity. Other pathogens, such as poliovirus, also require antibodies, produced by B cells, for containment. These different classes of immune attack (T cell or B cell) are controlled by different subpopulations of CD4 + T cells, commonly referred to as Th1 and Th2 cells.

The two types of Th cell subsets have been well characterized in a murine model and are defined by the cytokines they release upon activation. The Th1 subset secretes IL-2, IFN-γ and tumor necrosis factor, and mediates macrophage activation and delayed-type hypersensitivity response. The Th2 subset releases IL-4, IL-5, IL-6 and IL-10, which stimulate B cell activation. The Th1 and Th2 subsets are mutually inhibiting, so that IL-4 inhibits Th1-type responses, and IFN-γ inhibits Th2-type responses. Similar Th1 and Th2 subsets have been found in humans, with release of the identical cytokines observed in the murine model. Amplification of Th1-type immune responses is central to a reversal of disease state in many disorders, including disorders of the respiratory system such as tuberculosis, sarcoidosis, asthma, allergic rhinitis and lung cancers.

In one aspect, the compositions of the present invention include polypeptides that comprise at least one immunogenic epitope of a M. vaccae antigen, or a variant thereof. In specific embodiments, the inventive polypeptides comprise a sequence provided in SEQ ID NO: 61-77. Such polypeptides stimulate T cell proliferation, and/or interferon gamma secretion from T cells of individuals exposed to M. tuberculosis.

As used herein, the term “polypeptide” encompasses amino acid chains of any length, including full-length proteins (i.e., antigens), wherein the amino acid residues are linked by covalent peptide bonds. Thus, a polypeptide comprising an immunogenic epitope of one of the above antigens may consist entirely of the immunogenic epitope, or may contain additional sequences. The additional sequences may be derived from the native M. vaccae antigen or may be heterologous, and such sequences may (but need not) be immunogenic.

“Imunogenic,” as used herein, refers to the ability to elicit an immune response in a patient, such as a human, or in a biological sample. In particular, an immunogenic epitope is that portion of a polypeptide that is capable of stimulating cell proliferation, interleukin-12 production or interferon-γ production in biological samples comprising one or more cells selected from the group of T cells, NK cells, B cells and macrophages, where the cells are derived from a mycobacteria-immune individual. In general, an immunogenic epitope will stimulate proliferation of PBMC from mycobacteria-immune individuals at levels at least two-fold greater than that observed in control PBMC, determined using assay techniques detailed below in Example 1. Alternatively, or additionally, an immunogenic epitope will stimulate the production of interferon-γ in PBMC from mycobacteria-immune individuals at levels that are at least two-fold greater than those observed in control cells as determined by at least a two-fold increase in OD in an ELISA assay as detailed in Example 1. A mycobacteria-immune individual is one who is considered to be resistant to the development of mycobacterial infection by virtue of having mounted an effective T cell response to M. turberculosis , to environmental saprophytes, or to BCG. Such individuals may be identified based on a strongly positive (i.e., greater than about 10 mm diameter induration) intradermal skin test response to tuberculosis proteins (PPD), and an absence of any symptoms of tuberculosis infection. Polypeptides comprising at least an immunogenic epitope of one or more M. vaccae antigens may generally be used to induce protective immunity against tuberculosis in a patient and/or to stimulate an immune response in a patient.

In another aspect, the compositions of the present invention comprise isolated polynucleotides that encode an immunogenic epitope of a M. vaccae antigen. In specific embodiments, the inventive polynucleotides comprise a sequence of SEQ ID NO: 5-21. Complements of the inventive isolated polynucleotides, reverse complements of such isolated polynucleotides and reverse sequences of such isolated polynucleotides are also provided, together with variants of such sequences. The present invention also encompasses polynucleotide sequences that differ from the disclosed sequences but which, due to the degeneracy of the genetic code, encode a polypeptide which is the same as that encoded by a polynucleotide sequence disclosed herein.

The term “polynucleotide(s),” as used herein, means a single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases and includes DNA and corresponding RNA molecules, including HnRNA and mRNA molecules, both sense and anti-sense strands, and comprehends cDNA, genomic DNA and recombinant DNA, as well as wholly or partially synthesized polynucleotides. An HnRNA molecule contains introns and corresponds to a DNA molecule in a generally one-to-one manner. An mRNA molecule corresponds to an HnRNA and/or DNA molecule from which the introns have been excised. A polynucleotide may consist of an entire gene, or any portion thereof. Operable anti-sense polynucleotides may comprise a fragment of the corresponding polynucleotide, and the definition of “polynucleotide” therefore includes all such operable anti-sense fragments. Anti-sense polynucleotides and techniques involving anti-sense polynucleotides are well known in the art and are described, for example, in Robinson-Benion et al. “Antisense techniques,” Methods in Enzymol . 254:363-375, 1995; and Kawasaki et al. Artific. Organs 20:836-848, 1996.

The definition of the terms “complement”, “reverse complement” and “reverse sequence”, as used herein, is best illustrated by the following example. For the sequence 5′AGGACC 3′, the complement, reverse complement and reverse sequence are as follows:

complement 3′TCCTGG 5′

reverse complement 3′GGTCCT 5′

reverse sequence 5′CCAGGA 3′.

All of the polynucleotides and polypeptides described herein are isolated and purified, as those terms are commonly used in the art.

The compositions and methods of this invention also encompass variants of the above polypeptides and polynucleotides. Variants may be naturally occurring allelic variants, or non-naturally occurring variants. As used herein, the term “variant” covers any sequence which has at least about 30%, more preferably at least about 50%, more preferably yet at least about 75% and most preferably at least about 90% identical residues (either nucleotides or amino acids) to a sequence of the present invention. The percentage of identical residues is determined by aligning the two sequences to be compared, determining the number of identical residues in the aligned portion, dividing that number by the total length of the inventive, or queried, sequence and multiplying the result by 100.

Polynucleotide or polypeptide sequences may be aligned, and percentage of identical nucleotides in a specified region may be determined against another polynucleotide, using computer algorithms that are publicly available. Two exemplary algorithms for aligning and identifying the similarity of polynucleotide sequences are the BLASTN and FASTA algorithms. The similarity of polypeptide sequences may be examined using the BLASTP and FASTX algorithms. Both the BLASTN and BLASTP software are available on the NCBI anonymous FTP server under /blast/executables/. The BLASTN algorithm Version 2.0.6 [Sep. 16, 1998], set to the default parameters described in the documentation and distributed with the algorithm, is preferred for use in the determination of variants according to the present invention. The use of the BLAST family of algorithms, including BLASTN and BLASTP, is described in the publication of Altschul, Stephen F, et al. “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res . 25:3389-3402, 1997. The computer algorithm FASTA is available on the Internet. Version 3.1t11 August 1998, of the FASTA and FASTX algorithms, set to the default parameters described in the documentation and distributed with the algorithms, are preferred for use in the determination of variants according to the present invention. The use of the FASTA algorithm is described, for example, in Pearson W R and Lipman D J. Proc. Natl. Acad. Sci. USA 85:2444-2448, 1988; and Pearson W R. Methods in Enzymol . 183:63-98, 1990. The use of the FASTX algorithm is described, for example, in Pearson W R, et al., Genomics 46:24-36, 1997.

The following running parameters are preferred for determination of alignments and similarities using BLASTN that contribute to the E values and percentage identity: Unix running command: blastall -p blastn -d embldb -e 10 -G 0 -E 0 -r 1 -v 30 -b 30 -i queryseq -o results; and parameter default values: -p Program Name [String]; -d Database [String]; -e Expectation value (E) [Real]; -G Cost to open a gap (zero invokes default behavior) [Integer]; -E Cost to extend a gap (zero invokes default behavior) [Integer]; -r Reward for a nucleotide match (BLASTN only) [Integer]; -v Number of one-line descriptions (V) [Integer]; -b Number of alignments to show (B) [Integer]; -i Query File [File In]; -o BLAST report Output File [File Out] Optional. For BLASTP the following running parameters are preferred: blastall -p blastp -d swissprotdb -e 10 -G 0 -E 0 -v 30 -b 30 -i queryseq -o results; -p Program Name [String]; -d Database [String]; -e Expectation value (E) [Real]; -G Cost to open a gap (zero invokes default behavior) [Integer]; -E Cost to extend a gap (zero invokes default behavior) [Integer]; -v Number of one-line descriptions (v) [Integer]; -b Number of alignments to show (b) [Integer]; -I Query File [File In]; -o BLAST report Output File [File Out] Optional.

For determination of alignments and similarities using FASTX, the following UNIX command is preferred: fastx -E 10 -b 30 -H queryseq >output, while for FASTA, the following UNIX command is preferred: fasta -E 2 -b 30 -H -n queryseq >output.

The “hits” to one or more database sequences by a queried sequence produced by BLASTN, BLASTP, FASTA, FASTX or a similar algorithm, align and identify similar portions of sequences. The hits are arranged in order of the degree of similarity and the length of sequence overlap. Hits to a database sequence generally represent an overlap over only a fraction of the sequence length of the queried sequence.

The BLASTN and FASTA algorithms also produce “Expect” values for alignments. The Expect value (E) indicates the number of hits one can “expect” to see over a certain number of contiguous sequences by chance when searching a database of a certain size. The Expect value is used as a significance threshold for determining whether the hit to a database, such as the preferred EMBL database, indicates true similarity. For example, an E value of 0.1 assigned to a hit is interpreted as meaning that in a database of the size of the EMBL database, one might expect to see 0.1 matches over the aligned portion of the sequence with a similar score simply by chance. By this criterion, the aligned and matched portions of the sequences then have a probability of 90% of being the same. For sequences having an E value of 0.01 or less over aligned and matched portions, the probability of finding a match by chance in the EMBL database is 1% or less using the BLASTN or FASTA algorithm.

According to one embodiment, “variant” polynucleotides, with reference to each of the polynucleotides of the present invention, preferably comprise sequences having the same number or fewer nucleic acids than each of the polynucleotides of the present invention and producing an E value of 0.01 or less when compared to the polynucleotide of the present invention. That is, a variant polynucleotide is any sequence that has at least a 99% probability of being the same as the polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN or FASTA algorithms set at the default parameters. According to a preferred embodiment, a variant polynucleotide is a sequence having the same number or fewer nucleic acids than a polynucleotide of the present invention that has at least a 99% probability of being the same as the polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN or FASTA algorithms set at the default parameters.

In certain embodiments, variant polynucleotide sequences hybridize to the recited polynucleotide sequence under stringent conditions. As used herein, “stringent conditions” refers to prewashing in a solution of 6×SSC, 0.2% SDS; hybridizing at 65° C., 6×SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in 1×SSC, 0.1% SDS at 65° C. and two washes of 30 minutes each in 0.2×SSC, 0.1% SDS at 65° C. In other embodiments, variants of the recited polynucleotides and/or polypeptides may be isolated from mycobacterial species. In certain preferred embodiments, variants of the recited polypeptides possess similar activity to the recited polypeptides as determined, for example, by their ability to stimulate cell proliferation and/or the production of cytokines or interferon-γ in human PBMC, measured as described in detail below.

A polypeptide of the present invention may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

As used herein, the term “x-mer,” with reference to a specific value of “x,” refers to a polynucleotide comprising at least a specified number (“x”) of contiguous residues of any of the polynucleotides identified as SEQ ID NO: 5-21. The value of x may be from about 20 to about 600, depending upon the specific sequence.

Polynucleotides of the present invention comprehend polynucleotides comprising at least a specified number of contiguous residues (x-mers) of any of the polynucleotides identified as SEQ ID NO: 5-21 or their variants. According to preferred embodiments, the value of x is preferably at least 20, more preferably at least 40, more preferably yet at least 60, and most preferably at least 80. Thus, polynucleotides of the present invention include polynucleotides comprising a 20-mer, a 40-mer, a 60-mer, an 80-mer, a 100-mer, a 120-mer, a 150-mer, a 180-mer, a 220-mer a 250-mer, or a 300-mer, 400-mer, 500-mer or 600-mer of a polynucleotide identified as SEQ ID NO: 5-21 or a variant of one of the polynucleotides identified as SEQ ID NO: 5-21.

In general, the inventive polypeptides and polynucleotides, may be prepared using any of a variety of procedures. For example, polypeptides may be produced recombinantly by inserting a polynucleotide that encodes the polypeptide into an expression vector and expressing the polypeptide in an appropriate host. Any of a variety of expression vectors known to those of ordinary skill in the art may be employed. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a polynucleotide that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are E. coli , mycobacteria, insect, yeast or a mammalian cell line such as COS or CHO. The polynucleotides expressed in this manner may encode naturally occurring antigens, portions of naturally occurring antigens, or other variants thereof.

Polynucleotides of the present invention may be isolated by screening a M. vaccae genomic DNA library as described below in Example 1. Alternatively, polynucleotides encoding M. vaccae epitopes may be obtained by screening an appropriate M. vaccae cDNA or genomic DNA library for DNA sequences that hybridize to degenerate oligonucleotides derived from amino acid sequences of isolated epitopes. Suitable degenerate oligonucleotides may be designed and synthesized, and the screen may be performed as described, for example in Sambrook et al. Molecular cloning: a laboratory manual . CSHL Press: Cold Spring Harbor, N.Y., 1989. Polymerase chain reaction (PCR) may be employed to isolate a nucleic acid probe from genomic DNA, or a cDNA or genomic DNA library, using techniques well known in the art. The library screen may then be performed using the isolated probe.

Regardless of the method of preparation, the epitopes described herein have the ability to induce an immunogenic response. More specifically, as discussed above, the epitopes have the ability to induce cell proliferation and/or cytokine production (for example, interferon-γ and/or interleukin-12 production) in T cells, NK cells, B cells or macrophages derived from a mycobacteria-immune individual.

The selection of cell type for use in evaluating an immunogenic response to an epitope will depend on the desired response. For example, interleukin-12 production is most readily evaluated using preparations containing T cells, NK cells, B cells and/or macrophages derived from mycobacteria-immune individuals may be prepared using methods well known in the art. For example, a preparation of peripheral blood mononuclear cells (PBMCs) may be employed without further separation of component cells. PBMCs may be prepared, for example, using density centrifugation through Ficoll™ (Winthrop Laboratories, N.Y.). T cells for use in the assays described herein may be purified directly from PBMCs. Alternatively, an enriched T cell line reactive against mycobacterial proteins, or T cell clones reactive to individual mycobacterial proteins, may be employed. Such T cell clones may be generated by, for example, culturing PBMCs from mycobacteria-immune individuals with mycobacterial proteins for a period of 2-4 weeks. This allows expansion of only the mycobacterial protein-specific T cells, resulting in a line composed solely of such cells. These cells may then be cloned and tested with individual proteins, using methods well known in the art, to more accurately define individual T cell specificity. Assays for cell proliferation or cytokine production in T cells, NK cells, B cells or macrophages may be performed, for example, using the procedures described below.

Among the immunogenic epitopes, polypeptides and/or polynucleotides of the present invention, those having superior therapeutic properties may be distinguished based on the magnitude of the responses in the above assays and based on the percentage of individuals for which a response is observed. In addition, epitopes having superior therapeutic properties will not stimulate cell proliferation or cytokine production in vitro in cells derived from more than about 25% of individuals that are not mycobacteria-immune, thereby eliminating responses that are not specifically due to mycobacteria-responsive cells. Thus, those antigens that induce a response in a high percentage of T cell, NK cell, B cell or macrophage preparations from mycobacteria-immune individuals (with a low incidence of responses in cell preparations from other individuals) have superior therapeutic properties.

Epitopes with superior therapeutic properties may also be identified based on their ability to diminish the severity of M. tuberculosis infection, or other mycobacterial infection, in experimental animals, when administered as a vaccine. Suitable vaccine preparations for use in experimental animals are described in detail below.

Portions and other variants of the inventive polypeptides may be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, J. Am. Chem. Soc . 85:2149-2154, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems, Inc. (Foster City, Calif.), and may be operated according to the manufacturer's instructions. Variants of a native epitope may be prepared using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis. Sections of the DNA sequence may also be removed using standard techniques to permit preparation of truncated polypeptides.

The present invention also provides fusion proteins comprising a first and a second inventive polypeptide or, alternatively, a polypeptide of the present invention and a known M. tuberculosis antigen, such as the 38 kDa antigen described in Andersen and Hansen, Infect. Immun . 57:2481-2488, 1989, together with variants of such fusion proteins. In a related aspect, DNA constructs comprising a first and a second inventive polynucleotide are also provided. Preparation of a construct comprising multiple epitopes of the present invention and expression of the corresponding recombinant protein is detailed below in Example 4. In general, a poly-nucleotide encoding a fusion protein of the present invention is constructed using known recombinant DNA techniques to assemble separate DNA sequences encoding the first and second polypeptides into an appropriate expression vector. The 3′ end of a DNA sequence encoding the first polypeptide is ligated, with or without a peptide linker, to the 5′ end of a DNA sequence encoding the second polypeptide so that the reading frames of the sequences are in phase to permit mRNA translation of the two DNA sequences into a single fusion protein that retains the biological activity of both the first and the second polypeptides.

A peptide linker sequence may be employed to separate the first and the second polypeptides by a distance sufficient to ensure that each polypeptide fold into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39-46, 1985; Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258-8262, 1986; and U.S. Pat. Nos. 4,935,233 and 4,751,180. The linker sequence may be from 1 to about 50 amino acids in length. Peptide linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference. The ligated DNA sequences encoding the fusion proteins are cloned into suitable expression systems using techniques known to those of ordinary skill in the art.

In another aspect, the present invention provides methods for using one or more of the inventive polypeptides or fusion proteins (or polynucleotides encoding such polypeptides or fusion proteins) to induce protective immunity against disorders such as tuberculosis in a patient. As used herein, a “patient” refers to any warm-blooded animal, preferably a human. A patient may be afflicted with a disease, or may be free of detectable disease or infection. In other words, protective immunity may be induced to prevent or treat disorders.

In related aspects, the M. vaccae polynucleotides and polypeptides of the present invention may be employed to activate T cells and NK cells; to stimulate the production of cytokines (in particular Th1 class of cytokines) in human PBMC; to produce anti-epitope antibodies; and/or to induce long-term memory cells.

For use in such methods, the polypeptide, fusion protein or polynucleotide is generally present within a pharmaceutical composition or a vaccine. Pharmaceutical compositions may comprise one or more polypeptides, each of which may contain one or more of the above sequences (or variants thereof), and a physiologically acceptable carrier. Vaccines may comprise one or more of the above polypeptides and a non-specific immune response amplifier, such as an adjuvant or a liposome, into which the polypeptide is incorporated. Such pharmaceutical compositions and vaccines may also contain other mycobacterial antigens, either, as discussed above, incorporated into a fusion protein or present within a separate polypeptide.

Alternatively, a vaccine of the present invention may contain a polynucleotide encoding one or more polypeptides as described above, such that the polypeptide is generated in situ. In such vaccines, the polynucleotide may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacterial and viral expression systems. Appropriate nucleic acid expression systems contain the necessary DNA/RNA sequences for expression in the patient (such as a suitable promoter and terminator signal). Bacterial delivery systems involve the administration of a bacterium (such as Bacillus Calmette-Guerin) that expresses an immunogenic epitope of the polypeptide on its cell surface. In a preferred embodiment, the DNA and/or RNA may be introduced using a viral expression system (e.g., vaccinia or other poxvirus, retrovirus, or adenovirus), that may involve the use of a non-pathogenic, or defective, replication competent virus. Techniques for incorporating DNA and/or RNA into such expression systems are well known in the art. The DNA may also be “naked,” as described, for example, in Ulmer et al., Science 259:1745-1749, 1993 and reviewed by Cohen, Science 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells. Methods for the administration of polynucleotide sequences comprising DNA and/or RNA include those disclosed in U.S. Pat. Nos. 5,580,859 and 5,589,466.

A polynucleotide vaccine as described above may be administered simultaneously with or sequentially to either a polypeptide of the present invention or a known mycobacterial antigen, such as the 38 kDa antigen described above. For example, administration of DNA encoding a polypeptide of the present invention, may be followed by administration of an antigen in order to enhance the protective immune effect of the vaccine.

Routes and frequency of administration, as well as dosage, will vary from individual to individual and may parallel those currently being used in immunization using M. bovis BCG. In general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intradermal, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 and 3 doses may be administered for a 1-36 week period. Preferably, 3 doses are administered, at intervals of 3-4 months, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of polypeptide or polynucleotide that, when administered as described above, is capable of raising an immune response in a patient sufficient to protect the patient from mycobacterial infection for at least 1-2 years. In general, the amount of polypeptide present in a dose (or produced in situ by the polynucleotide in a dose) ranges from about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 mg, and preferably from about 100 pg to about 1 μg. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 ml to about 5 ml.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactic galactide) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Pat. Nos. 4,897,268 and 5,075,109.

Any of a variety of adjuvants may be employed in the vaccines of this invention to non-specifically enhance the immune response. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a non-specific stimulator of immune responses, such as lipid A, Bordetella pertussis, M. turberculosis , or, as discussed below, M. vaccae . Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Freund's Complete Adjuvant (Difco Laboratories, Detroit, Mich.), and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.). Other suitable adjuvants include alum, biodegradable microspheres, monophosphoryl lipid A and Quil A.

The following examples are offered by way of illustration and not by way of limitation.

EXAMPLE 1

Cloning and Selection of Immunogenic M. Vacae Epitopes

M. vaccae (ATCC Number 15483, Manassas, Va.) was cultured in medium 90 (yeast extract, 2.5 g/l; tryptone, 5 g/l; glucose, 1 g/l) at 37° C. for four days. Genomic DNA was isolated from these cells following standard protocols and then digested with restriction endonuclease Sau3A under conditions that produced DNA fragments of approximately 0.25 kb. The fragments were purified using the QIAquick PCR clean-up system (Qiagen, Venlo, The Netherlands).

To express the cloned M. vaccae DNA in three different reading frames, the pcDNA3 expression vector (Invitrogen, Carlsbad, Calif.) was modified by insertion of a human growth hormone signal peptide (to facilitate recombinant protein secretion) amplified with three different 3′ primers. These primers allowed the insertion of one or two extra base pairs into the PCR product to shift the reading frame of the expressed polypeptide. The primers were AD105 (human growth hormone 5′ primer; SEQ ID NO: 1) and the three human growth hormone (hGH) 3′ primers AD106, AD107 and AD108 (SEQ ID NO: 2-4, respectively). From these PCR fragments, most of the hGH sequence downstream of the leader sequence cleavage site was removed by digestion with the restriction endonuclease BsgII. The hGH PCR fragments were then cloned into the pcDNA3 expression vector following digestion with the restriction endonucleases HindIII and BamHI. The nucleotide sequence of the inserted fragments are given in SEQ ID NO: 5-7, with the corresponding amino acid sequences being provided in SEQ ID NO: 61-63, respectively. Three expression libraries (one for each of the three reading frames) were constructed by cloning the 0.25 kb M. vaccae PCR fragments, prepared as described above, into the BamHI cloning site of the chimeric pcDNA3/human growth hormone vectors (pcDNA3-hGH1′, pcDNA3-hGH2′ and pcDNA3-hGH3′). Replica lift master plates were made of bacterial colonies transformed with the library constructs and stored. Plasmid DNA, prepared from these colonies, was divided into 500 pools, each containing DNA from 40 to 50 plasmids. The DNA was transfected into COS7 cells using lipofectamine (BRL Life Technologies, Gaithersburg Md.) and the immunogenic properties of the products of each group were determined by a spleen cell assay, wherein the production of IFN-γ in cultures of spleen cells obtained from mice primed with heat-killed M. vaccae was determined by ELISA as described below.

Plasmid pools that encoded recombinant polypeptides eliciting an immune response (as determined by the ability to increase IFN-γ production in the spleen cell assay), were subdivided into smaller pools containing 10 plasmids each and these pools were again transfected into COS7 cells. The culture supernatants of these cells were subjected to the spleen cell assay as described above.

After three rounds of screening, 120 plasmids were identified that encoded recombinant polypeptides stimulating spleen cells of heat-killed M. vaccae -immunised mice to produce IFN-γ. The 120 supernatants of COS7 cells transfected with these plasmids were screened in two additional assays, namely the mouse memory assay and the human peripheral blood mononuclear cell (PBMC) assay. In the mouse long-term memory assay, mice were injected with a sub-lethal dose of 10 4 colony forming units (CFU) of M. tuberculosis . After 4 weeks, the mice were treated with antibiotics for a further 4 weeks to cure them of M. tuberculosis infection, followed by a resting period of 4 weeks. A second injection of live M. tuberculosis (5×10 5 CFU) was given before the immunogenicity of the plasmid products was measured four days later using the spleen cell assay described above.

In the PBMC assay, the 120 supernatants of COS7 cells transfected with the plasmids were screened for the ability to induce T-cell proliferation and IFN-γ production in peripheral blood cells from mycobacteria-immune human donors. These donors were known to be PPD (purified protein derivative from M. tuberculosis ) positive and their T cells were shown to proliferate and produce IFN-γ in response to PPD. Donor PBMCs and COS7 supernatants were cultured in medium comprising RPMI 1640 supplemented with 10% (v/v) autologous serum, penicillin (60 μg/ml), streptomycin (100 μg/ml), and glutamine (2 mM). After 3 days, 50 μl of medium was removed from each well for the determination of IFN-γ levels, as described below. The plates were cultured for a further 4 days and then pulsed with 1 μCi/well of tritiated thymidine for 18 hours, harvested and tritium uptake determined using a scintillation counter. Supernatants that stimulated proliferation in two replicates at levels two-fold greater than the proliferation observed in cells cultured in medium alone were considered positive.

IFN-γ was measured using an enzyme-linked immunosorbent assay (ELISA) as follows. ELISA plates were coated with a mouse monoclonal antibody directed to human IFN-γ (Endogen, Wobural, Mass.) by incubating the wells with 1 μg/ml antibody in phosphate-buffered saline (PBS) for 4 hours at 4° C. Wells were blocked with PBS containing 0.2% Tween 20 for 1 hour at room temperature. The plates were then washed four times in PBS/0.2% Tween 20, and samples diluted 1:2 in culture medium in the ELISA plates were incubated overnight at room temperature. The plates were again washed, and a biotinylated polyclonal rabbit anti-human IFN-γ serum (Endogen), diluted to 1 μg/ml in PBS, was added to each well. The plates were then incubated for 1 hour at room temperature, washed, and horseradish peroxidase-coupled avidin A (Vector Laboratories, Burlingame, Calif.) was added at a 1:4,000 dilution in PBS. After a further 1 hour incubation at room temperature, the plates were washed and orthophenylenediamine (OPD) substrate added. The reaction was stopped after 10 minutes with 10% (v/v) HCl. The optical density (OD) was determined at 490 nm. Supernatants that resulted in both replicates giving an OD two-fold greater than the mean OD from cells cultured in medium alone were considered positive.

From the results of these two assays, 59 plasmids were identified that encoded recombinant polypeptides containing immunogenic determinants, or epitopes. These epitopes were found to elicit an immune response in mice and humans, and are cross-reactive with M. tuberculosis immunogenic determinants inducing long term responses. These plasmids were tested for their ability to induce protective immunity in the mouse model of tuberculosis as follows. Each plasmid (100 μg of DNA) was injected IM. in the tibialis anterior of anaesthetised mice, three times every three weeks. After nine weeks, the mice were challenged with M. tuberculosis (5×10 5 CFU). Organ homogenates from lungs and spleens were prepared in week 12 and plated out on 7H9 medium supplemented with oleic acid-albumin-dextrose-catalase (OADC) to determine the number of CFU present in each homogenate. Results were recorded after a two-week incubation period.

Using the protocols described above, eight plasmids containing immunogenic epitopes were selected. After identification of the putative open reading frames (ORFs) in these constructs, the M. vaccae fragments comprising only the ORF-portion were sub-cloned into pcDNA3-hGH′ as described above. These plasmids were called DNA5, DNA9, DNA26, DNA27, DNA29, DNA37, DNA44 and DNA45. Three ORFs, referred to as A, B and C, were identified in DNA9. Open reading frames B and C were in the reverse orientation and were discarded. ORF A was cloned separately and the resulting plasmid was called DNA9A. The determined genomic DNA sequences of the inserts of DNA5, DNA9A, DNA26, DNA27, DNA29, DNA37, DNA42, DNA44 and DNA45 are given in SEQ ID NO: 13-21, respectively, with the predicted amino acid sequences of the corresponding ORFs being provided in SEQ ID NO: 69-77, respectively. More than one epitope was identified in the inserts of the plasmids DNA5 and DNA27. These epitopes were not separated by cloning and were tested as multiple epitopes in all the assays. The determined genomic DNA sequences of epitope 1, epitope 2 and epitope 3 of DNA5, and of epitope 1 and epitope 2 of DNA27 are given in SEQ ID NO: 8-12, respectively, with the corresponding predicted amino acid sequences being provided in SEQ ID NO: 64-68, respectively. The determined epitope DNA sequences were compared to sequences in the EMBL DNA database using the FASTA computer algorithm. The corresponding predicted protein sequences (DNA translated to protein in each of 6 reading frames) were compared to sequences in the SwissProt database using the computer algorithm FASTX. Comparisons of DNA sequences provided in SEQ ID NO: 8-21 to sequences in the EMBL DNA database (using FASTA) and amino acid sequences provided in SEQ ID NO: 64-77 to sequences in the SwissProt database (using FASTX) were made as of Mar. 21, 1999.

The predicted amino acid sequences of DNA5 epitope 2, DNA27 epitope 1, DNA9A, DNA29, DNA37, DNA44 and DNA45 (provided in SEQ ID NO: 65, 67, 70, 73, 74, 76 and 77, respectively) were found to have less than 50% identity, determined as described above, to sequences in the SwissProt database using FASTX. The predicted amino acid sequences of DNA5 epitopes 1 and 3 (provided in SEQ ID NO: 64 and 66, respectively) were found to have less than 75% identity, determined as described above, to sequences in the SwissProt database using FASTX. No matches were found to the predicted amino acid sequence of DNA27 epitope 2 and DNA26 (provided in SEQ ID NO: 68 and 71, respectively). Table 1, below, shows the results of the comparison of the inventive amino acid sequences with those in the SwissProt database using FASTX as described above, wherein “No. of identical residues” represents the number of identical residues within the aligned portion.

	TABLE 1
			Length of	No. of	% of
	SEQ ID	Length	alignment	identical	identical
	NO:	(residues)	(residues)	residues	residues
DNA5,	64	13	11	8	61
epitope 1
DNA5,	65	32	31	10	32
epitope 2
DNA5,	66	26	25	14	53
epitope 3
DNA9A	70	75	68	24	32
DNA26	71	97	No Hits
DNA27,	67	38	30	16	42
epitope 1
DNA27,	68	11	No Hits
epitope 2
DNA29	73	46	40	17	37
DNA37	74	87	80	26	32
DNA44	76	44	35	17	38
DNA45	77	59	52	21	35

EXAMPLE 2

Expression of Recombinant Epitopes in Prokaryotic and Eukaryotic Cells

Epitope DNA was subcloned into vectors for expression of polypeptides in bacterial and eukaryotic cells. The bacterial expression vector was a modified pET16 vector (Novagen, Madison, Wis.). Inserts from all the plasmids except for DNA9, were amplified with primers AD136 and AD133 (SEQ ID NO: 22 and 23, respectively) and cloned by blunt-end ligation into the pET16 vector that was EcoRI-digested and end-filled with DNA polymerase PfuI (Stratagene, La Jolla Calif.). The insert of DNA9A was amplified with AD250 and AD251 (SEQ ID NO: 24 and 25, respectively) and cloned into the pET16 vector as described above.

To express the polypeptides in eukaryotic cells, the pcDNA3 vector (Invitrogen) was modified to include a histidine tag at the 3′ end of the cloning site. This was done by cloning the double-stranded oligonucleotide AD 180/AD 181 into pcDNA3 digested with BamHI and EcoRI. The sequences of oligonucleotides AD180 and AD181 are given in SEQ ID NO: 26 and 27, respectively. Plasmid inserts were amplified with the hGH-specific N-terminus 5′ primer AD134 (SEQ ID NO: 28) and an epitope-specific 3′ end primer, using the pcDNA3-hGH′ constructs as DNA template. The sequences of the epitope-specific 3′ primers AD151 (DNA5), AD153 (DNA26), AD154 (DNA27), AD155 (DNA29), AD158 (DNA42), AD159 (DNA44), AD160 (DNA45), AD167 (DNA37) and AD182 (DNA9) are listed in SEQ ID NO: 29-37, respectively.

This vector was again modified to remove excess sequence (42 nucleotides) between the hGH leader sequence and the expressed sequence, so that the hGH′ sequence in this construct was reduced to the leader sequence and the first 5 N-terminal amino acids of the hGH sequence only. Using the pcDNA3-hGH3′ construct as DNA template, the shortened fusion partner was amplified by PCR using primers AD105 (SEQ ID NO: 1) and AD222 (SEQ ID NO: 38). Cloning into pcDNA3-His was done at the HindIII and BamHI sites and the resulting construct was called pcDNA3-hGH-1s/His. The determined DNA sequence of the hGH-fusion partner cloned into pcDNA3-hGH-1s is given in SEQ ID NO: 39 and the corresponding amino acid sequence in SEQ ID NO: 78. The construct consisting of the insert from DNA9A was prepared by PCR amplification using primers AD223 and AD226 (SEQ ID NO: 40 and 41, respectively).

EXAMPLE 3

Immunogenicity of Recombinant Epitope Constructs

This example describes the results of immunogenicity studies performed with eight selected recombinant epitopes in either DNA or recombinant polypeptide form.

A. Stimulation of Human Peripheral Blood Mononuclear Cells (PBMC) to proliferate and secrete Interferon gamma (IFN-γ) in vitro

The recombinant epitopes (1 and 10 μg) expressed by the pET16 bacterial expression system were cultured with human PBMC at 37° C. After 48 hours, IFN-γ secretion was measured by enzyme-linked immunoassay (ELISA) following standard procedures. Parallel cultures were pulsed with tritiated thymidine and DNA synthesis was used to assess PBMC proliferation. For comparison, cells were also cultured with Purified Protein Derivative (PPD) from M. tuberculosis and with PBS as a negative control.

As shown in Table 2, all recombinant epitopes have the ability to stimulate IFN-γ production in at least some PBMC samples. Of the 12 PBMC samples tested, 10 were PPD positive, i.e., the PBMCs from these samples produced IFN-γ when cultured with PPD, and 2 were PPD-negative. PBMC responses were considered positive when the amount of IFN-γ produced was at least 3-fold higher than the IFN-γ produced by the PBS control samples. Recombinant epitopes 5 (corresponding to DNA5) and 44 (corresponding to DNA44) stimulated IFN-γ production in 100% of the PPD + samples. Recombinant epitope 27 (corresponding to DNA27) stimulated IFN-γ production in 80% of the PPD + samples. Recombinant epitopes 26 and 37 (corresponding to DNA26 and DNA37, respectively) stimulated IFN-γ production in 70% of the PPD + samples, whereas epitope 45 (corresponding to DNA45) stimulated 20% PPD + of the PBMC samples. PBMCs from PPD − samples did not respond significantly to any of the recombinant epitopes. This demonstrates that the epitopes are immunogenic in humans and trigger a recall response in samples from donors that were previously exposed to mycobacteria.

TABLE 2

Stimulation of IFN-γ production in human PBMC by recombinant epitopes

TABLE 2
Stimulation of IFN-γ production in human PBMC by recombinant epitopes
	PBS	PPD	Recombinant Epitopes
PBMC	control	control	26	37	44	45	5	27
G97022	<0.1	0.16	0.3	0.3	0.4	<0.1	0.5	0.1
G97037	<0.1	0.3	0.3	0.3	0.8	0.2	0.3	0.3
G97001	<0.1	4.5	0.6	1	3.5	0.2	1.8	1.7
G97008	<0.1	4.4	0.16	0.5	4	<0.1	0.73	0.9
G97011	0.25	4.9	0.9	0.5	1.2	0.25	2.8	1.2
G97030	<0.1	1.8	0.5	0.2	3.5	0.1	1.8	3
G97033	0.12	4.5	0.5	0.25	3.4	0.2	1.7	1
G97010	<0.1	>4	>4	>4	>4	1	>4	>4
G97028	<0.1	>4	>4	>4	>4	1.2	>4	>4
G97020	<0.1	1	0.3	0.25	>4	<0.1	1.5	0.5
G97032	<0.1	>4	0.5	1.2	>4	<0.1	1.4	0.5
G97035	<0.1	3.5	0.4	3.5	>4	<0.1	1	1
* Results are expressed as IFN-γ in ng/ml

Immunogenicity of the epitopes in humans was further demonstrated by the proliferative response of the human PBMC samples to both PPD and recombinant epitopes. The ability of the recombinant epitopes to stimulate PBMC proliferation was expressed as a stimulation index. A proliferation stimulus is considered positive when it is 5 times greater than the mean background proliferation produced by the medium-only control. As shown in Table 3, all recombinant epitopes were found to have the ability to stimulate PBMC proliferation in at least some of the human PBMC samples. Recombinant epitopes 26 and 27 stimulated PBMC proliferation in 92% of the samples, while recombinant epitopes 5, 37 and 44 stimulated proliferation in 83% of the samples. Epitope 45 stimulated PBMC proliferation in 17% of the samples. Stimulation of PBMC by PPD was 83%.

TABLE 3

Stimulation of PMBC Poliferation

TABLE 3
Stimulation of PMBC proliferation
Human	Recombinant epitopes
PBMC	PPD	5	26	27	37	44	45
G97022	5*	12	14	3	20	20	1
G97037	35	12	25	20	15	30	1
G97001	5	6	6	5	8	7	1
G97008	60	20	30	15	40	60	2
G97011	40	33	30	27	30	30	3
G97030	100	140	120	140	120	140	30
G97033	20	12	12	11	10	15	1
G97010	2	4	2	6	2	4	2
G97028	60	48	60	40	55	52	12
G97020	10	10	10	8	10	10	1
G97032	45	30	35	33	38	42	2
G97035	3	4	5	6	3	4	2
*Results of human PBMC proliferation are expressed as Stimulation Index.

B. Immunization of mice with DNA epitopes

Protective immunity against subsequent infection with M. tuberculosis was induced in BALB/cByJ mice after injection of DNA encoding eight of the recombinant epitopes in pcDNA-hGH′/His or pcDNA3-hGH1s/His constructs.

Induction of protective immunity was considered positive when a mean 0.5 log reduction in CFU in lung homogenates, compared to the mean CFUs from non-immunised control mice, was observed following subsequent infection with M. tuberculosis . A plasmid without an insert was used as control. The reduction in CFUs after epitope DNA immunisation was also compared with the known immunogenicity of M. bovis BCG. The results clearly show a reduction in CFUs in all the mice tested, suggesting the induction of protective immunity by the recombinant epitope DNA. In six of the groups, the reduction in CFUs was greater than 50% and in three of the groups the reduction was comparable to that induced by injection with M. bovis BCG.

TABLE 4

Protective Immunity in Mice Induced by Genetic Immunisation with Eight pcDNA-hGH′/His and pcDNA3-hGH1s/His Constructs

TABLE 4
Protective immunity in mice induced by genetic immunisation with
eight pcDNA-hGH′/His and pcDNA3-hGHls/His constructs
	SEQ
Epitope	ID	Number of	Number of mice	% Mice with
construct	NO:	Mice	with reduced CFUs	Reduced CFUs
Control		14	2	14
plasmid
DNA5	13	11	4	36
DNA9	14	13	7	55
DNA26	15	10	7	70
DNA27	16	13	7	55
DNA29	17	13	7	55
DNA37	18	13	8	62
DNA44	20	13	6	46
DNA45	21	13	8	62
M. bovis BCG		23	17	74

The induction of cytotoxic T lymphocytes (CTL), cytokines (IFN-γ, IL-4, IL-6 and IL-10), and proliferative and antibody responses upon genetic immunisation with eight pcDNA-hGH′/His or pcDNA3-hGH1s/His constructs were assessed as follows.

CTL assay:

Cytolytic (CTL) activity in spleen cells of DNA-immunised BALB/cByJ mice was measured following a standard two-step procedure using the MHC haplotype matching target cells, BALB-3T3 (ATCC No. CRL-163, American Type Culture Collection, Manassas, Va.). Target cells were prepared by transfecting BALB/3T3 cells with eight pcDNA-hGH′/His or pcDNA3-hGH1s/His epitope DNA constructs. Stably transfected cell lines were produced by geneticin selection (G418; Gibco BRL Life Technologies) and single cells were isolated by limiting dilution. Clones expressing epitopes were selected by RT-PCR using primers AD105 and AD181 (SEQ ID NO: 1 and 27, respectively). Spleen cells of DNA-immunised mice were cultured in cDMEM. enriched with 10% FCS in the presence of mytomycin-treated BALB-3T3 cells transfected with matching epitope DNA to re-stimulate cytotoxic T cells in vitro. Cultures were incubated at 37° C. under 10% CO 2 for 6 days. Cytolytic activities were monitored by incubating a fraction of each stimulated cell culture with DNA-matched target cells that were pulsed with 51 Chromium, and measuring 51 Chromium release in the supernatant of cell cultures. As shown in Table 5, specific CTL activity was detected in the spleens of mice immunised with four of the DNA constructs tested.

Cytokine and proliferative responses:

Cytokine production and proliferative responses of spleen cells from DNA-immunised BALB/cByJ mice were assessed following in vitro re-stimulation with recombinant epitopes. Cytokine and proliferative responses were measured by ELISA and 3H-thymidine pulse, respectively, as described above. As shown in Table 5, spleen cells from the six groups tested produced the Th1 cytokine IFN-γ. No Th2 cytokines (e.g. IL-4, IL-6 and IL-10) were detected in supernatants of stimulated cells. Proliferative responses were low and detected in spleen cells from two immunised groups only.

Antibody responses

Blood samples from three DNA-immunised BALB/cByJ mice were collected two weeks after the last DNA injection and sera were prepared according to standard procedures. The presence of anti-epitope antibodies was determined by ELISA. The wells of a microtitre plate were coated with 500 ng of recombinant epitope. Antibody titres were measured by adding serial dilutions of serum into the wells. Bound antibodies were detected according to ELISA procedures as described above. As shown in Table 5, anti-epitope antibodies were detected in two blood samples tested. ELISA assays were also performed to determine whether the antibodies belonged to the IgG1 or IgG2a subclasses, using standard protocols. The results showed that the antibodies belonged to the IgG2a subclass, which is characteristic of a Th1 antibody response.

The data summarised in Table 5 indicate that immunisation with epitope DNA induced an immune response in mice. Furthermore, the cellular and humoral responses detected in the DNA-immunised mice demonstrated that a Th1 response was generated.

TABLE 5

Cytotoxic Lymphocyte Induction, Cytokine Responses, Proliferation and Antibody Production Induced in Mice by Genetic Immunisation with Eight pcDNA-hGH′/His or pcDNA3-hGH1s/His constructs

TABLE 5
Cytotoxic lymphocyte induction, cytokine responses, proliferation and antibody production induced
in mice by genetic immunisation with eight pcDNA-hGH′/His or pcDNA3-hGHls/His constructs.
Epitope	SEQ ID	CTL induction	Cytokine responses	Proliferation	Antibodies
constructs	NO:	(% Specific lysis)*	(IFN-γ in ng/ml)**	(Stimulation index)	(titer)
DNA5	13	30	15	not detected	not detected
DNA9A	14	10	NT***	NT	NT
DNA26	15	not detected	30	7	not detected
DNA27	16	not detected	33	3	1/100
DNA29	17	not detected	NT	NT	NT
DNA37	18	not detected	18	not detected	not detected
DNA44	20	25	23	not detected	1/100
DNA45	21	20	12	not detected	not detected
*Data shown is the mean % lysis from spleen cells of three mice. Non-specific lysis of control cells was deducted.
**Data shown is the mean IFN-γ in ng/ml obtained from triplicates of spleen cell cultures from three mice. Background IFN-γ produced by control cells was 5-7 ng/ml.
***NT = Not Tested

EXAMPLE 4

Cloning Strategy for M. Vaccae Multi-epitope Constructs

The eight epitopes assayed in Example 4 were assembled to form multi-epitope constructs. Specifically, the DNA was amplified with primers containing a BglII5′-extension and BamHI 3′-extension and was sequentially cloned into the BamHI site of pcDNA3/hGH1s/His. The primers were AD223, AD226, AD229, AD230, AD231, AD232, AD233, AD234, AD235, AD236, AD256, AD258, AD259, AD260, AD261 and AD262 (SEQ ID NO: 40-55, respectively).

The insert of plasmid DNA9A was cloned first into the BamHI site of pcDNA3-hGH1s/His. The BamHI site of the vector was reconstituted at the 3′ end of the cloning junction only and all other inserts except DNA5 were sequentially cloned into the same site. The insert of plasmid DNA5 was cloned last by blunt ligation into the end-filled BamHI site of pcDNA3-hGH1s/His. Following this protocol, various combinations of epitopes were cloned into the pcDNA3-hGH1s/His vector. The determined DNA sequences of three multi-epitope constructs consisting of 8-mer multi-epitopes (called ME/A, ME/B and ME/D) are shown in SEQ ID NO: 56-58, respectively, and the predicted corresponding amino acid sequences in SEQ ID NO: 79-81, respectively. Each one of these multi-epitope constructs includes each one of the 8 epitopes, but in a different order.

For expression of multi-epitope recombinant proteins in bacteria, the inserts of plasmids ME/A, ME/B and ME/D were subcloned into the modified expression vector pET16. All 8-mer epitope DNA combinations had DNA9A and DNA5 at the 5′ and 3′ end, respectively. The plasmid inserts were amplified using primers AD272 and AD273 (SEQ ID NO: 59 and 60, respectively) and the purified amplified fragments cloned by blunt-end ligation into the pET16 vector that was EcoRI-digested and end-filled with DNA polymerase PfuI (Stratagene). Recombinant protein was expressed using E. coli host cells according to the manufacturer's protocol and purified using standard protocols.

EXAMPLE 5

Immunization of Mice with M. Vaccae Multi-epitope Constructs

This example illustrates the protective immunity against subsequent infection with M. tuberculosis in BALB/cByJ mice after injection of multi-epitope constructs in either DNA or recombinant polypeptide form.

BALB/cByJ mice were divided into three groups of six mice that received different treatments. Mice in Group 1 were immunized intraperitoneally with one dose of 500 μg M. bovis BCG or PBS. Group 2 mice were immunized three times intramuscularly in the tibialis anterior with 100 μg ME/D DNA or empty vector DNA at three week intervals. Mice in Group 3 were immunized intraperitoneally at three week intervals with either 1 or 2 doses of 50 μg recombinant ME/D in IFA, or 50 μg control protein in IFA. The control protein GV14B consisted of a non-naturally occurring protein derived from DNA encoding the M. vaccae -homologue of mycobacterial Elongation factor G and cloned into pET16g3 in reverse orientation.

Three weeks after the last immunization, the mice were challenged with live M. tuberculosis (5×10 5 CFU). Organ homogenates from lungs and spleens were prepared after a further three weeks and plated out on 7H9 medium supplemented with oleic acid-albumin-dextrose-catalase (OADC) to determine the number of CFU present in each homogenate. Results were recorded after a two-week incubation period.

Induction of protective immunity was considered positive when a mean 0.5 log reduction in CFU in lung and spleen homogenates, compared to the mean CFUs from non-immunized control mice, was observed following subsequent infection with M. tuberculosis . The reduction in CFUs after immunization with ME/D DNA or recombinant ME/D polypeptide was compared with the known immunogenicity of M. bovis BCG. The results ( FIG. 1 ) show a reduction in CFUs in the lungs and spleens from mice immunized with the ME/D DNA as well as the recombinant ME/D construct. The protective immunity of the ME/D DNA and the rME/D polypeptide demonstrated by the reduction in both lung and spleen CFUs was greater than the reduction in lung CFU after immunization with single epitope constructs (Table 4).

EXAMPLE 6

Immunogenicity of M. Vaccae Multi-epitope Constructs

This example describes the results of immunogenicity studies performed with three multi-epitope constructs in either DNA or recombinant polypeptide form.

A. Recombinant multi-epitope constructs ME/A, ME/B and ME/D stimulate mouse lymph node cells to proliferate and secrete IFN-γ in vitro

The recombinant multi-epitope constructs rME/A, rME/B and rME/D were screened for their ability to induce T-cell proliferation and IFN-γ in murine lymph node cells. For this assay, BALB/cByJ mice were immunized subcutaneously in each footpad with 10 μg of the recombinant multi-epitope constructs rME/A, rME/B or rME/C diluted in an equal volume of IFA. Mice from the control group received PBS in IFA. Mice were sacrificed after nine days and the lymph nodes removed. Lymph node cells were cultured in medium comprising DMEM supplemented with 10% (v/v) autologous serum, penicillin (60 μg/ml), streptomycin (100 μg/ml), and glutamine (2 mM) in the presence of 0, 0.125, 0.25 or 0.5 μM. rME/A, rME/B or rME/D, as well as the control protein GV14B. After 3 days, 50 μl of medium was removed from each well for the determination of IFN-γ levels, as described above. The plates were cultured for a further 4 days and then pulsed with 1 μCi/well of tritiated thymidine for 18 hours. Cells were harvested and tritium uptake determined using a scintillation counter. Supernatants that stimulated proliferation in two replicates at levels two-fold greater than the proliferation observed in cells cultured in medium alone were considered positive.

Results from the murine proliferation experiments are shown in FIGS. 2A-D . All three of the recombinant multi-epitope constructs induced a proliferatvie response in lymph node cells from immunized mice. The levels of proliferation induced by the three recombinant multi-epitope constructs rME/A, rME/B and rME/D ( FIGS. 2A , B and C, respectively) were similar, showing that the constructs were antigenically identical. No proliferation was obtained from control mice immunized with PBS (FIG. 2 D).

The levels of IFN-γ secreted by stimulated lymph node cells from mice immunized with rME/A, rME/B or rME/D are shown in FIGS. 3A-C , respectively. All three recombinant multi-epitope constructs stimulated IFN-γ secretion by lymph node cells, with the highest levels stimulated with rME/B (FIG. 3 B). Cells from control mice stimulated with PBS secreted undetectable amounts of IFN-γ (FIG. 3 D). These results suggested that immunization with the multi-epitope constructs induced a Th1 immune response in the mice.

B. Recombinant multi-epitope construct ME/D and ME/D DNA stimulate lymph node and spleen cells from mice immunized by different routes to proliferate and secrete IFN-γ in vitro

In these experiments, lymph node or spleen cells from mice immunized subcutaneously, intraperitoneally or intramuscularly with the recombinant multi-epitope construct rME/D or the DNA form of the multi-epitope construct ME/D were stimulated to induce T-cell proliferation and IFN-γ production. BALB/cByJ mice were immunized either subcutaneously in each footpad with one dose of 10 μg rME/D in IFA, intraperitoneally with one dose of 50 μg rME/D in IFA, or intramuscularly with three doses at 3 week intervals with 100 μg ME/D DNA. Control mice were immunized with PBS by the three different immunization routes. After nine days, mice immunized by the subcutaneous and intraperitoneal routes were sacrificed and the lymph nodes (subcutaneous immunization) or spleen cells (intraperitoneal immunization) removed. Spleen cells from mice immunized by intramuscular injection were harvested 15 days after the last immunization. Proliferation and IFN-γ production by these cells were determined as described above.

Results from these experiments are presented in FIGS. 4A-B and FIGS. 5A-B . In FIG. 4A , specific proliferative responses by lymph node and spleen cells from mice immunized with rME/D or ME/D DNA are shown. In comparison, FIG. 4B shows the low proliferation by cells from control mice. Similarly, lymph node and spleen cells from mice immunized with rME/D or ME/D DNA were stimulated to secrete IFN-γ ( FIG. 5A ) while low levels of IFN-γ was secreted by lymph node and spleen cells from control mice immunized with PBS.

C. Single epitopes from multi-epitope constructs stimulate lymph node and spleen cells from mice immunized with recombinant multi-epitope construct rME/D or ME/D DNA by different routes to proliferate and secrete IFN-γ in vitro

In these experiments, lymph node and spleen cells from mice immunized with the recombinant multi-epitope construct rME/D or the DNA form of the multi-epitope construct ME/D by different immunization routes were re-stimulated with the recombinant form of the single epitopes DNA5, DNA9, DNA26, DNA27, DNA29, DNA37, DNA44 and DNA45. The experimental procedure was the same as outlined above. Results from these experiments are shown in FIGS. 6A-B and FIGS. 7A-B . Specific proliferative responses and IFN-γ secretion were detected in cells re-stimulated with epitopes DNA5, DNA9A, DNA26, DNA37 and DNA44 (FIG. 6 A and FIG. 7 A). Proliferation and IFN-γ production by epitopes DNA27, DNA29 and DNA45 were shown in at least one immunization group. Low levels of proliferation and IFN-γ production was observed in cells from control mice immunized with PBS (FIG. 6 B and FIG. 7 B). The data indicates that the epitopes are all individually antigenic when presented to the immune system as part of a multi-component immunogen.

D. Cytokine production

The cytokine production by spleen cells from mice immunized with the DNA form of the multi-epitope construct ME/D and re-stimulated with rME/A or rME/D was determined as follows. BALB/cByJ mice were immunized intramuscularly with three doses at three week intervals of 100 μg ME/D DNA. Fifteen days after the last injection, mice were sacrificed and the spleen cells removed. The spleen cells were re-stimulated with rME/A, rME/D or the control protein GV14B and the supernatants screened for cytokine production following standard procedures. Cytokine production by the spleen cells is given in Table 6.

TABLE

Cytokines secreted by splenocytes from BAL/cBYJ mice immunized with ME DNA

TABLE 6
Cytokines secreted by splenocytes from BALB/cByJ mice immunized with ME DNA
	IL-2*		IL-4*		IL-6*
Plasmid	rME/A	rME/D	GV14B		rME/A	rME/D	GV14B		rME/A	rME/D	GV14B
ME/A	122	125	<50		42	56	39		147	196	<30
ME/B	267	200	<50		20	<10	<10		79	56	<30
ME/D	96	77	<50		13	<10	<10		131	98	<30
Control	<50	<50	<50		<10	<10	<10		<30	<30	<30
*Cytokine concentration measured in pg/ml, with a standard error of <10%

As shown in Table 6, IL-2 and IL-6 were secreted by spleen cells of mice stimulated with rME/A and rME/D. IL-2 is a cytokine secreted during a Th1-type immune response, providing further evidence that the multi-epitope constructs elicit a Th1-type immune response. The cytokine IL-6 plays an important role in the immunity of mice to tuberculosis (Ladel et al., Infec. Imm . 65: 4843-4849, 1997). No secretion of IL-4, a Th2-type cytokine, was detected.

E. Antibody production

Blood samples from BALB/cByJ mice immunized with ME/D were collected two weeks after the last DNA injection and sera prepared according to standard procedures. The presence of anti-ME/D antibodies was determined by ELISA. As shown in FIG. 8B , high titres of IgG2a antibodies reacting with rME/A and rME/D were detected, but no IgG1 antibodies (FIG. 8 A). The presence of IgG2a antibodies is characteristic of a Th1 -type immune response.

F. Induction in mice of long-term memory responses by recombinant epitopes and recombinant multi-epitope construct rME/D.

The induction of long-term memory responses in mice infected with M. tuberculosis and immunized with either recombinant epitopes rDNA5, rDNA9A, rDNA26, rDNA27, rDNA37, rDNA44 or rDNA45, or recombinant multi-epitope construct ME/D was determined as follows. In the mouse long-term memory assay, BALB/cByJ mice were injected with a sub-lethal dose of 10 4 colony forming units (CFU) of M. tuberculosis . After 4 weeks, the mice were treated with antibiotics for a further 4 weeks to cure them of M. tuberculosis infection, followed by a resting period of 8 weeks. A second injection of live M. tuberculosis (5×10 5 CFU) was given before the immunogenicity of the recombinant constructs was measured three days later using the spleen cell assay described above. Spleen cells were stimulated with 2 μM. of recombinant epitope or with 1, 0.33, 0.11, 0.03 or 0.01 μM. rME/D. The levels of IFN-γ production determined in the spleen assay are shown in FIGS. 9A-C . Spleen cells from control mice were stimulated with the unrelated protein GV14B (FIG. 9 B). Other controls in this experiments included stimulation with medium only, 2 μg/ml ConA, 10 μg/ml PPD and 10 μg/ml M. vaccae (FIG. 9 A). Recombinant ME/D stimulated memory T cells from mice infected with M. tuberculosis to produce large amounts of IFN-γ in a dose-dependent manner (FIG. 9 B). The production of IFN-γ in this assay is indicative of the cross-reactivity of ME/D with M. tuberculosis antigens that induced long-term immune responses. Antigenic determinants cross-reacting with the M. tuberculosis antigens appears to be located on epitopes DNA5, DNA9A, DNA26, DNA27 and DNA44 (FIG. 9 B).

EXAMPLE 7

Effect of Stimulation of Human Peripheral Blood Mononuclear Cells (PBMC) with Recombinant Single Epitopes and Recombinant Multi-epitope Constructs

A. Stimulation of Human Peripheral Blood Mononuclear Cells (PBMC) to proliferate and secrete Interferon gamma (IFN-γ) in vitro

The recombinant epitopes and recombinant multi-epitope constructs expressed by the pET16 bacterial expression system were cultured with human PBMC at 37° C. After 48 hours, IFN-γ secretion was measured by enzyme-linked immunoassay (ELISA) as described above. Parallel cultures were pulsed with tritiated thymidine and DNA synthesis was used to assess PBMC proliferation. Results of these experiments are shown in FIGS. 10A-B and FIGS. 11A-B . The recombinant multi-epitope constructs stimulated human PBMC to secrete IFN-γ and proliferate ( FIGS. 10A and B , respectively). These responses were dose-dependent and of greater magnitude than the responses induced by the individual recombinant epitopes (FIGS. 11 A and B).

B. Stimulation of human PBMC by recombinant single epitopes and recombinant multi-epitope constructs rME/A and rME/D to secrete cytokines in vitro

Cytokine production of human PBMC were assessed following in vitro re-stimulation with recombinant single epitopes or recombinant rME/A or rME/D as follows. Cells were stimulated with 2 μM of the recombinant single epitopes rDNA5, rDNA9A, rDNA26, rDNA27, rDNA29, rDNA37, rDNA44 or rDNA45, or 0.5 μM. rME/A or rME/D. Cells in the control groups were stimulated with 2 μM of GV14B or 10 μg/ml PPD. Cytokine responses was measured by ELISA following standard procedures. As shown in Table 7, below, human PBMC stimulated with the recombinant single epitopes, or with rME/A or rME/D produced the Th1 cytokines IFN-γ and TNF-α. These recombinant epitopes also induced secretion of IL-10. No IL-5, a Th2 cytokine, was detected in supernatants of stimulated cells. Low levels of cytokines were secreted in response to stimulation with the control antigen, and all cytokines tested were secreted by human PBMC after stimulation with PPD.

TABLE 7
Cytokine secretion by human PBMC after in vitro stimulation
with recombinant single epitopes and rME
	Recombinant single epitopes		Controls
	DNA	DNA	DNA	DNA	DNA	DNA	DNA	DNA	rME	GV14
Cytokine	5	9A	26	27	29	37	44	45	rME/A	rME/D	B	PPD
IFN-γ	4.7	2.8	4.1	0.06	3.6	4.3	0.45	0.78	4.4	3.2	<0.05	3.96
TNF-α	4.6	<0.05	1.2	0.1	3.5	2.3	0.5	<0.05	3.9	3.8	0.2	0.85
IL-10	0.75	<0.05	0.9	0.15	0.98	0.83	0.59	<0.05	1.17	1.12	0.07	0.34
IL-5	0.08	<0.05	<0.05	0.06	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05	0.06

Although the present invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, changes and modifications can be carried out without departing from the scope of the invention which is intended to be limited only by the scope of the appended claims.

81 1 29 DNA Artificial Sequence Made in a lab 1gagagagaaa gcttatggct acaggctcc 29 2 30 DNA Artificial Sequence Made in a lab 2aaggaagggg atcccgaagc cacagctgcc 30 3 29 DNA Artificial Sequence Made in a lab 3aaggaagggg atccgaagcc acagctgcc 29 4 31 DNA Artificial Sequence Made in a lab 4aaggaagggg atcccggaag ccacagctgc c 31 5 146 DNA Mycobacterium vaccae 5aagcttatgg ctacaggctc ccggacgtcc ctgctcctgg cttttggcct gctctgcctg 60ccctggcttc aagagggcag tgccttccca accattccct tatccaggct ttttgacaac 120gctatgcagc tgtggcttcg ggatcc 146 6 145 DNA Mycobacterium vaccae 6aagcttatgg ctacaggctc ccggacgtcc ctgctcctgg cttttggcct gctctgcctg 60ccctggcttc aagagggcag tgccttccca accattccct tatccaggct ttttgacaac 120gctatgcagc tgtggcttcg gatcc 145 7 147 DNA Mycobacterium vaccae 7aagcttatgg ctacaggctc ccggacgtcc ctgctcctgg cttttggcct gctctgcctg 60ccctggcttc aagagggcag tgccttccca accattccct tatccaggct ttttgacaac 120gctatgcagc tgtggcttcc gggatcc 147 8 39 DNA Mycobacterium vaccae 8atcgccgcca ccggcccggt gcccggcacc gcgtggatc 39 9 96 DNA Mycobacterium vaccae 9gttcgtcagt acccgaagct cttgagagct aaggccaatt gggaagatac ttggaccttc 60ccatcaatag aggaaaagca tcgccctagg ggatcc 96 10 75 DNA Mycobacterium vaccae 10gtagcgggcc cggtgtttcg agtgaacttg ggcagggcaa tcccatcgcg cgcagcccgc 60gcagcggaaa tccac 75 11 114 DNA Mycobacterium vaccae 11atcacgcagg taggccgtcc agccgtactc ttcgccccag aacagcggtg ccgtcgccgc 60gcagaccagc ggtcctgccg ccagatacac ccaggcggtg gccggcatgt ccag 114 12 33 DNA Mycobacterium vaccae 12atcgtggcca gcgcgcgcgg cacggtggag atc 33 13 210 DNA Mycobacterium vaccae 13atcgccgcca ccggcccggt gcccggcacc gcgtggatcg ttcgtcagta cccgaagctc 60ttgagagcta aggccaattg ggaagatact tggaccttcc catcaataga ggaaaagcat 120cgccctaggg gatccgtagc gggcccggtg tttcgagtga acttgggcag ggcaatccca 180tcgcgcgcag cccgcgcagc ggaaatccac 210 14 697 DNA Mycobacterium vaccae 14atctactcga ccttcgccga ccgggcgtac ccgggtggcc tgacgtactc cggccatccg 60ctggcgaccg cctgcgcggt cgcgacgatc aacgcgatgg aagacgaagg catggtggcc 120aacgctgccc gcatcggcga gcaggtgctc ggaccgggtc tgcgcgatct cgccgcccgg 180caccgttcgg tcggcgaagt ccgcggcctc ggcgtcttct gggcggatct cggtgaggtc 240gtcctgcggc gactggaatg ccacgttgtt gacgacgatg tccagtccgc caagctgttt 300caccgtgtcc tcgaccaccg cgcggcagtg cgccggctcg gccaggtcgc cgggcaggcg 360gaccgcccgc tgtccggcct cttcgatcag tgccagcgca tcccgaaccg cggcggcgta 420cgcgtcggcg tcggcgccgc gcacggccgg gcacggggcc acctcccgct ccgggcaggc 480gggtccgtgg accgcagcac ggccgagtcg tttggtacag gtgcgcaccc cgctgaaccg 540ggccatcagc gccgccgcct cggtcgcgtc gctgcgggac cggaacgggc ccaccgcgct 600gtcggtgcgc ggcgtgcgga cggtggagaa ccgggggaag ggttcgtcgg tcagcgtcac 660ccaccaccac cggtgcggga acttcgaccg ccggttg 697 15 291 DNA Mycobacterium vaccae 15atcagttcgg ccctggtcgc cagcccgccg agggcagcca gttccgctcc ggcgtcgatc 60gggttgggtc cgtccggcca gcacaccagc atccacccga ggtcgagcaa cgggtccccg 120acggtgcaca tctcccagtc gatgaacgcc gcgagctcgg ggacgtcgcg gcgcagcagc 180acgttgttca gatggcagtc gccgtgcatg atcccgggtt cggcgtcgtc gggcctgcgc 240gagtccagcc agtcggcgag cacatgcacc gacgggaacg actcgggcgc g 291 16 147 DNA Mycobacterium vaccae 16atcacgcagg taggccgtcc agccgtactc ttcgccccag aacagcggtg ccgtcgccgc 60gcagaccagc ggtcctgccg ccagatacac ccaggcggtg gccggcatgt ccagatcgtg 120ccagcgcgc gcggcacggt ggagatc 147 17 138 DNA Mycobacterium vaccae 17atcgcgcggc tgtgcgggaa ggacgaggcc gtagcggcgt tgcactacgt cgccccggtt 60ggcgagaagc aggactacat cgaccgagcc ttgcgcaaca tcgggccgta tctgccagct 120gaggttcccg ctctcgtc 138 18 261 DNA Mycobacterium vaccae 18gatcggcagg catcacgaac agtaagcggt gttccggttg aatccaatgt gctgtcagca 60ggcatccgat gccgaacacc gaccacgcga gcagtcgcaa tctgtctcgc gaccctggcg 120tcacgcggcg tcgtggctcc gcaacccgcc ggcgatgtcg cgcgcgccgc tgcggccggc 180tctccatggc cggttcgttc agtcgctcgt ccggtggctg ttctgcgaac gggcccgccg 240ccccgtcgtc cgtccgatac g 261 19 279 DNA Mycobacterium vaccae 19gatctcgttg cgcgtccgcg agatctgcga ccggtacgac ctgccctaca ccaccgggtc 60cttcctggcg cagtacggca agtcgtggcg cacgatcgcg aaactgtcgc tgccggacaa 120gttcctgcgc gacaccgccg acgacgcccc ggagacccgc agcgagcgga tgttcgccga 180actggatccg tcggagcggc gcgggctgaa gtcggccatc gccgcggtgc ggtcgcgccg 240gcgcgccaag gtcgctgcga aagccgcgaa gatcgcgat 279 20 132 DNA Mycobacterium vaccae 20gatccagaac gggccggtct gcgggttgag gtcctcggtg cccagtgccg tcgacgcgac 60gtcgtcggcg ctggtgatgc ggccgccgta ggcgtcctcg gtccacaacg tcagcaccgt 120gcccgggcgg at 132 21 177 DNA Mycobacterium vaccae 21gatcagctcg gggagccggg tgcccagcaa cgccagcgtg ggaagcaccg agaccggcgc 60gatgtgcccg cgcagcagcg cccagccgtg caccccgcgg gaccgggccc cgcggaccgc 120gtcggagtcg accccggccg ccaccgccgc gcgcgtggtc agcatcagcc acgggat 177 22 15 DNA Artificial Sequence Made in a lab 22cgcagctgtg gcttc 15 23 22 DNA Artificial Sequence Made in a lab 23ttacttaggt tactagtgga tc 22 24 23 DNA Artificial Sequence Made in a lab 24cgatctactc gaccttcgcc gac 23 25 24 DNA Artificial Sequence Made in a lab 25ttacgcccag aagacgccga ggcc 24 26 26 DNA Artificial Sequence Made in a lab 26gatcccatca ccatcaccat cactga 26 27 26 DNA Artificial Sequence Made in a lab 27ggtagtggta gtggtagtga ctttaa 26 28 20 DNA Artificial Sequence Made in a lab 28atggctacag gctcccggac 20 29 34 DNA Artificial Sequence Made in a lab 29gagagagaga tctgtggatt tccgctgcgc gggc 34 30 34 DNA Artificial Sequence Made in a lab 30gagagagaga tctcgcgccc gagtcgttcc cgtc 34 31 34 DNA Artificial Sequence Made in a lab 31gagagagaga tctgatctcc accgtgccgc gcgc 34 32 34 DNA Artificial Sequence Made in a lab 32gagagagaga tctgacgaga gcgggaacct cagc 34 33 34 DNA Artificial Sequence Made in a lab 33gagagagaga tctatcgcga tcttcgcggc tttc 34 34 34 DNA Artificial Sequence Made in a lab 34gagagagaga tctatccgcc cgggcacggt gctg 34 35 34 DNA Artificial Sequence Made in a lab 35gagagagaga tctatcccgt ggctgatgct gacc 34 36 36 DNA Artificial Sequence Made in a lab 36gagagagaga tctcgtatcg gacggacgac gggacg 36 37 35 DNA Artificial Sequence Made in a lab 37gagagagagg atcccaaccg gcggtcgaag ttccc 35 38 36 DNA Artificial Sequence Made in a lab 38aaggaaggaa aaggatccgg gaatggttgg gaaggc 36 39 126 DNA Artificial Sequence Made in a lab 39aagcttatgg ctacaggctc ccggacgtcc ctgctcctgg cttttggcct gctctgcctg 60ccctggcttc aagagggcag tgccttccca accattcccg gatcccacca tcatcaccat 120cactga 126 40 35 DNA Artificial Sequence Made in a lab 40gagagagaga tctatctact cgaccttcgc cgacc 35 41 37 DNA Artificial Sequence Made in a lab 41aaggaaggaa ggatcccgcc cagaagacgc cgaggcc 37 42 34 DNA Artificial Sequence Made in a lab 42gagagagaga tctatcagtt cggccctggt cgcc 34 43 37 DNA Artificial Sequence Made in a lab 43aaggaaggaa ggatcccgcg cccgagtcgt tcccgtc 37 44 35 DNA Artificial Sequence Made in a lab 44gagagagaga tctgatcggc aggcatcacg aacag 35 45 37 DNA Artificial Sequence Made in a lab 45aaggaaggaa ggatcccgta tcggacggac gacgggg 37 46 34 DNA Artificial Sequence Made in a lab 46gagagagaga tctgatccag aacgggccgg tctg 34 47 37 DNA Artificial Sequence Made in a lab 47aaggaaggaa ggatccatcc gcccgggcac ggtgctg 37 48 35 DNA Artificial Sequence Made in a lab 48gagagagaga tctgatcagc tcggggagcc gggtg 35 49 37 DNA Artificial Sequence Made in a lab 49aaggaaggaa ggatccatcc cgtggctgat gctgacc 37 50 22 DNA Artificial Sequence Made in a lab 50tatcgccgcc accggcccgg tg 22 51 22 DNA Artificial Sequence Made in a lab 51cgtggatttc cgctgcgcgg gc 22 52 33 DNA Artificial Sequence Made in a lab 52gagagagaga tctatcacgc aggtaggccg tcc 33 53 37 DNA Artificial Sequence Made in a lab 53aaggaaggaa ggatccgatc tccaccgtgc cgcgcgc 37 54 35 DNA Artificial Sequence Made in a lab 54gagagagaga tctatcgcgc ggctgtgcgg gaagg 35 55 37 DNA Artificial Sequence Made in a lab 55aaggaaggaa ggatccgacg agagcgggaa cctcagc 37 56 1749 DNA Artificial Sequence Made in a lab 56atggctacag gctcccggac gtccctgctc ctggcttttg gcctgctctg cctgccctgg 60cttcaagagg gcagtgcctt cccaaccatt cccggatcta tctactcgac cttcgccgac 120cgggcgtacc cgggtggcct gacgtactcc ggccatccgc tggcgaccgc ctgcgcggtc 180gcgacgatca acgcgatgga agacgaaggc atggtggcca acgctgcccg catcggcgag 240caggtgctcg gaccgggtct gcgcgatctc gccgcccggc accgttcggt cggcgaagtc 300cgcggcctcg gcgtcttctg ggcgggatct gatccagaac gggccggtct gcgggttgag 360gtcctcggtg cccagtgccg tcgacgcgac gtcgtcggcg ctggtgatgc ggccgccgta 420ggcgtcctcg gtccacaacg tcagcaccgt gcccgggcgg atggatctga tcggcaggca 480tcacgaacag taagcggtgt tccggttgaa tccaatgtgc tgtcagcagg catccgatgc 540cgaacaccga ccacgcgagc agtcgcaatc tgtctcgcga ccctggcgtc acgcggcgtc 600gtggctccgc aacccgccgg cgatgtcgcg cgcgccgctg cggccggctc tccatggccg 660gttcgttcag tcgctcgtcc ggtggctgtt ctgcgaacgg gcccgccgcc ccgtcgtccg 720tccgatacgg gatctgatca gctcggggag ccgggtgccc agcaacgcca gcgtgggaag 780caccgagacc ggcgcgatgt gcccgcgcag cagcgcccag ccgtgcaccc cgcgggaccg 840ggccccgcgg accgcgtcgg agtcgacccc ggccgccacc gccgcgcgcg tggtcagcat 900cagccacggg atggatctat cagttcggcc ctggtcgcca gcccgccgag ggcagccagt 960tccgctccgg cgtcgatcgg gttgggtccg tccggccagc acaccagcat ccacccgagg 1020tcgagcaacg ggtccccgac ggtgcacatc tcccagtcga tgaacgccgc gagctcgggg 1080acgtcgcggc gcagcagcac gttgttcaga tggcagtcgc cgtgcatgat cccgggttcg 1140gcgtcgtcgg gcctgcgcga gtccagccag tcggcgagca catgcaccga cgggaacgac 1200tcgggcgcgg gatctatcac gcaggtaggc cgtccagccg tactcttcgc cccagaacag 1260cggtgccgtc gccgcgcaga ccagcggtcc tgccgccaga tacacccagg cggtggccgg 1320catgtccaga tcgtggccag cgcgcgcggc acggtggaga tcggatctat cgcgcggctg 1380tgcgggaagg acgaggccgt agcggcgttg cactacgtcg ccccggttgg cgagaagcag 1440gactacatcg accgagcctt gcgcaacatc gggccgtatc tgccagctga ggttcccgct 1500ctcgtcggat ctatcgccgc caccggcccg gtgcccggca ccgcgtggat cgttcgtcag 1560tacccgaagc tcttgagagc taaggccaat tgggaagata cttggacctt cccatcaata 1620gaggaaaagc atcgccctag gggatccgta gcgggcccgg tgtttcgagt gaacttgggc 1680agggcaatcc catcgcgcgc agcccgcgca gcggaaatcc acggatccca tcaccatcac 1740catcactga 1749 57 1749 DNA Artificial Sequence Made in a lab 57atggctacag gctcccggac gtccctgctc ctggcttttg gcctgctctg cctgccctgg 60cttcaagagg gcagtgcctt cccaaccatt cccggatcta tctactcgac cttcgccgac 120cgggcgtacc cgggtggcct gacgtactcc ggccatccgc tggcgaccgc ctgcgcggtc 180gcgacgatca acgcgatgga agacgaaggc atggtggcca acgctgcccg catcggcgag 240caggtgctcg gaccgggtct gcgcgatctc gccgcccggc accgttcggt cggcgaagtc 300cgcggcctcg gcgtcttctg ggcgggatct atcagttcgg ccctggtcgc cagcccgccg 360agggcagcca gttccgctcc ggcgtcgatc gggttgggtc cgtccggcca gcacaccagc 420atccacccga ggtcgagcaa cgggtccccg acggtgcaca tctcccagtc gatgaacgcc 480gcgagctcgg ggacgtcgcg gcgcagcagc acgttgttca gatggcagtc gccgtgcatg 540atcccgggtt cggcgtcgtc gggcctgcgc gagtccagcc agtcggcgag cacatgcacc 600gacgggaacg actcgggcgc gggatctgat cggcaggcat cacgaacagt aagcggtgtt 660ccggttgaat ccaatgtgct gtcagcaggc atccgatgcc gaacaccgac cacgcgagca 720gtcgcaatct gtctcgcgac cctggcgtca cgcggcgtcg tggctccgca acccgccggc 780gatgtcgcgc gcgccgctgc ggccggctct ccatggccgg ttcgttcagt cgctcgtccg 840gtggctgttc tgcgaacggg cccgccgccc cgtcgtccgt ccgatacggg atctgatcag 900ctcggggagc cgggtgccca gcaacgccag cgtgggaagc accgagaccg gcgcgatgtg 960cccgcgcagc agcgcccagc cgtgcacccc gcgggaccgg gccccgcgga ccgcgtcgga 1020gtcgaccccg gccgccaccg ccgcgcgcgt ggtcagcatc agccacggga tggatctatc 1080acgcaggtag gccgtccagc cgtactcttc gccccagaac agcggtgccg tcgccgcgca 1140gaccagcggt cctgccgcca gatacaccca ggcggtggcc ggcatgtcca gatcgtggcc 1200agcgcgcgcg gcacggtgga gatcggatct atcgcgcggc tgtgcgggaa ggacgaggcc 1260gtagcggcgt tgcactacgt cgccccggtt ggcgagaagc aggactacat cgaccgagcc 1320ttgcgcaaca tcgggccgta tctgccagct gaggttcccg ctctcgtcgg atctgatcca 1380gaacgggccg gtctgcgggt tgaggtcctc ggtgcccagt gccgtcgacg cgacgtcgtc 1440ggcgctggtg atgcggccgc cgtaggcgtc ctcggtccac aacgtcagca ccgtgcccgg 1500gcggatggat ctatcgccgc caccggcccg gtgcccggca ccgcgtggat cgttcgtcag 1560tacccgaagc tcttgagagc taaggccaat tgggaagata cttggacctt cccatcaata 1620gaggaaaagc atcgccctag gggatccgta gcgggcccgg tgtttcgagt gaacttgggc 1680agggcaatcc catcgcgcgc agcccgcgca gcggaaatcc acggatccca tcaccatcac 1740catcactga 1749 58 1749 DNA Artificial Sequence Made in a lab 58atggctacag gctcccggac gtccctgctc ctggcttttg gcctgctctg cctgccctgg 60cttcaagagg gcagtgcctt cccaaccatt cccggatcta tctactcgac cttcgccgac 120cgggcgtacc cgggtggcct gacgtactcc ggccatccgc tggcgaccgc ctgcgcggtc 180gcgacgatca acgcgatgga agacgaaggc atggtggcca acgctgcccg catcggcgag 240caggtgctcg gaccgggtct gcgcgatctc gccgcccggc accgttcggt cggcgaagtc 300cgcggcctcg gcgtcttctg ggcgggatct gatccagaac gggccggtct gcgggttgag 360gtcctcggtg cccagtgccg tcgacgcgac gtcgtcggcg ctggtgatgc ggccgccgta 420ggcgtcctcg gtccacaacg tcagcaccgt gcccgggcgg atggatctat cagttcggcc 480ctggtcgcca gcccgccgag ggcagccagt tccgctccgg cgtcgatcgg gttgggtccg 540tccggccagc acaccagcat ccacccgagg tcgagcaacg ggtccccgac ggtgcacatc 600tcccagtcga tgaacgccgc gagctcgggg acgtcgcggc gcagcagcac gttgttcaga 660tggcagtcgc cgtgcatgat cccgggttcg gcgtcgtcgg gcctgcgcga gtccagccag 720tcggcgagca catgcaccga cgggaacgac tcgggcgcgg gatctgatca gctcggggag 780ccgggtgccc agcaacgcca gcgtgggaag caccgagacc ggcgcgatgt gcccgcgcag 840cagcgcccag ccgtgcaccc cgcgggaccg ggccccgcgg accgcgtcgg agtcgacccc 900ggccgccacc gccgcgcgcg tggtcagcat cagccacggg atggatctga tcggcaggca 960tcacgaacag taagcggtgt tccggttgaa tccaatgtgc tgtcagcagg catccgatgc 1020cgaacaccga ccacgcgagc agtcgcaatc tgtctcgcga ccctggcgtc acgcggcgtc 1080gtggctccgc aacccgccgg cgatgtcgcg cgcgccgctg cggccggctc tccatggccg 1140gttcgttcag tcgctcgtcc ggtggctgtt ctgcgaacgg gcccgccgcc ccgtcgtccg 1200tccgatacgg gatctatcac gcaggtaggc cgtccagccg tactcttcgc cccagaacag 1260cggtgccgtc gccgcgcaga ccagcggtcc tgccgccaga tacacccagg cggtggccgg 1320catgtccaga tcgtggccag cgcgcgcggc acggtggaga tcggatctat cgcgcggctg 1380tgcgggaagg acgaggccgt agcggcgttg cactacgtcg ccccggttgg cgagaagcag 1440gactacatcg accgagcctt gcgcaacatc gggccgtatc tgccagctga ggttcccgct 1500ctcgtcggat ctatcgccgc caccggcccg gtgcccggca ccgcgtggat cgttcgtcag 1560tacccgaagc tcttgagagc taaggccaat tgggaagata cttggacctt cccatcaata 1620gaggaaaagc atcgccctag gggatccgta gcgggcccgg tgtttcgagt gaacttgggc 1680agggcaatcc catcgcgcgc agcccgcgca gcggaaatcc acggatccca tcaccatcac 1740catcactga 1749 59 23 DNA Artificial Sequence Made in a lab 59cgatctactc gaccttcgcc gac 23 60 24 DNA Artificial Sequence Made in a lab 60tcagtggatt tccgctgcgc gggc 24 61 46 PRT Mycobacterium vaccae 61Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu 1 5 10 15Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Phe Pro Thr Ile Pro Leu 20 25 30Ser Arg Leu Phe Asp Asn Ala Met Gln Leu Trp Leu Arg Asp 35 40 45 62 46 PRT Mycobacterium vaccae 62Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu 1 5 10 15Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Phe Pro Thr Ile Pro Leu 20 25 30Ser Arg Leu Phe Asp Asn Ala Met Gln Leu Trp Leu Arg Ile 35 40 45 63 46 PRT Mycobacterium vaccae 63Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu 1 5 10 15Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Phe Pro Thr Ile Pro Leu 20 25 30Ser Arg Leu Phe Asp Asn Ala Met Gln Leu Trp Leu Pro Gly 35 40 45 64 13 PRT Mycobacterium vaccae 64Ile Ala Ala Thr Gly Pro Val Pro Gly Thr Ala Trp Ile 1 5 10 65 32 PRT Mycobacterium vaccae 65Val Arg Gln Tyr Pro Lys Leu Leu Arg Ala Lys Ala Asn Trp Glu Asp 1 5 10 15Thr Trp Thr Phe Pro Ser Ile Glu Glu Lys His Arg Pro Arg Gly Ser 20 25 30 66 25 PRT Mycobacterium vaccae 66Val Ala Gly Pro Val Phe Arg Val Asn Leu Gly Arg Ala Ile Pro Ser 1 5 10 15Arg Ala Ala Arg Ala Ala Glu Ile His 20 25 67 38 PRT Mycobacterium vaccae 67Ile Thr Gln Val Gly Arg Pro Ala Val Leu Phe Ala Pro Glu Gln Arg 1 5 10 15Cys Arg Arg Arg Ala Asp Gln Arg Ser Cys Arg Gln Ile His Pro Gly 20 25 30Gly Gly Arg His Val Gln 35 68 11 PRT Mycobacterium vaccae 68Ile Val Ala Ser Ala Arg Gly Thr Val Glu Ile 1 5 10 69 70 PRT Mycobacteerium vaccae 69Ile Ala Ala Thr Gly Pro Val Pro Gly Thr Ala Trp Ile Val Arg Gln 1 5 10 15Tyr Pro Lys Leu Leu Arg Ala Lys Ala Asn Trp Glu Asp Thr Trp Thr 20 25 30Phe Pro Ser Ile Glu Glu Lys His Arg Pro Arg Gly Ser Val Ala Gly 35 40 45Pro Val Phe Arg Val Asn Leu Gly Arg Ala Ile Pro Ser Arg Ala Ala 50 55 60Arg Ala Ala Glu Ile His65 70 70 75 PRT Mycobacterium vaccae 70Ile Tyr Ser Thr Phe Ala Asp Arg Ala Tyr Pro Gly Gly Leu Thr Tyr 1 5 10 15Ser Gly His Pro Leu Ala Thr Ala Cys Ala Val Ala Thr Ile Asn Ala 20 25 30Met Glu Asp Glu Gly Met Val Ala Asn Ala Ala Arg Ile Gly Glu Gln 35 40 45Val Leu Gly Pro Gly Leu Arg Asp Leu Ala Ala Arg His Arg Ser Val 50 55 60Gly Glu Val Arg Gly Leu Gly Val Phe Trp Ala65 70 75 71 97 PRT Mycobacterium vaccae 71Ile Ser Ser Ala Leu Val Ala Ser Pro Pro Arg Ala Ala Ser Ser Ala 1 5 10 15Pro Ala Ser Ile Gly Leu Gly Pro Ser Gly Gln His Thr Ser Ile His 20 25 30Pro Arg Ser Ser Asn Gly Ser Pro Thr Val His Ile Ser Gln Ser Met 35 40 45Asn Ala Ala Ser Ser Gly Thr Ser Arg Arg Ser Ser Thr Leu Phe Arg 50 55 60Trp Gln Ser Pro Cys Met Ile Pro Gly Ser Ala Ser Ser Gly Leu Arg65 70 75 80Glu Ser Ser Gln Ser Ala Ser Thr Cys Thr Asp Gly Asn Asp Ser Gly 85 90 95Ala 72 49 PRT Mycobacterium vaccae 72Ile Thr Gln Val Gly Arg Pro Ala Val Leu Phe Ala Pro Glu Gln Arg 1 5 10 15Cys Arg Arg Arg Ala Asp Gln Arg Ser Cys Arg Gln Ile His Pro Gly 20 25 30Gly Gly Arg His Val Gln Ile Val Ala Ser Ala Arg Gly Thr Val Glu 35 40 45Ile 73 46 PRT Mycobacterium vaccae 73Ile Ala Arg Leu Cys Gly Lys Asp Glu Ala Val Ala Ala Leu His Tyr 1 5 10 15Val Ala Pro Val Gly Glu Lys Gln Asp Tyr Ile Asp Arg Ala Leu Arg 20 25 30Asn Ile Gly Pro Tyr Leu Pro Ala Glu Val Pro Ala Leu Val 35 40 45 74 87 PRT Mycobacterium vaccae 74Asp Arg Gln Ala Ser Arg Thr Val Ser Gly Val Pro Val Glu Ser Asn 1 5 10 15Val Leu Ser Ala Gly Ile Arg Cys Arg Thr Pro Thr Thr Arg Ala Val 20 25 30Ala Ile Cys Leu Ala Thr Leu Ala Ser Arg Gly Val Val Ala Pro Gln 35 40 45Pro Ala Gly Asp Val Ala Arg Ala Ala Ala Ala Gly Ser Pro Trp Pro 50 55 60Val Arg Ser Val Ala Arg Pro Val Ala Val Leu Arg Thr Gly Pro Pro65 70 75 80Pro Arg Arg Pro Ser Asp Thr 85 75 93 PRT Mycobacterium vaccae 75Asp Leu Val Ala Arg Pro Arg Asp Leu Arg Pro Val Arg Pro Ala Leu 1 5 10 15His His Arg Val Leu Pro Gly Ala Val Arg Gln Val Val Ala His Asp 20 25 30Arg Glu Thr Val Ala Ala Gly Gln Val Pro Ala Arg His Arg Arg Arg 35 40 45Arg Pro Gly Asp Pro Gln Arg Ala Asp Val Arg Arg Thr Gly Ser Val 50 55 60Gly Ala Ala Arg Ala Glu Val Gly His Arg Arg Gly Ala Val Ala Pro65 70 75 80Ala Arg Gln Gly Arg Cys Glu Ser Arg Glu Asp Arg Asp 85 90 76 44 PRT Mycobacterium vaccae 76Asp Pro Glu Arg Ala Gly Leu Arg Val Glu Val Leu Gly Ala Gln Cys 1 5 10 15Arg Arg Arg Asp Val Val Gly Ala Gly Asp Ala Ala Ala Val Gly Val 20 25 30Leu Gly Pro Gln Arg Gln His Arg Ala Arg Ala Asp 35 40 77 59 PRT Mycobacterium vaccae 77Asp Gln Leu Gly Glu Pro Gly Ala Gln Gln Arg Gln Arg Gly Lys His 1 5 10 15Arg Asp Arg Arg Asp Val Pro Ala Gln Gln Arg Pro Ala Val His Pro 20 25 30Ala Gly Pro Gly Pro Ala Asp Arg Val Gly Val Asp Pro Gly Arg His 35 40 45Arg Arg Ala Arg Gly Gln His Gln Pro Arg Asp 50 55 78 39 PRT Artificial Sequence Made in a lab 78Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu 1 5 10 15Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Phe Pro Thr Ile Pro Gly 20 25 30Ser His His His His His His 35 79 582 PRT Artificial Sequence Made in a lab 79Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu 1 5 10 15Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Phe Pro Thr Ile Pro Gly 20 25 30Ser Ile Tyr Ser Thr Phe Ala Asp Arg Ala Tyr Pro Gly Gly Leu Thr 35 40 45Tyr Ser Gly His Pro Leu Ala Thr Ala Cys Ala Val Ala Thr Ile Asn 50 55 60Ala Met Glu Asp Glu Gly Met Val Ala Asn Ala Ala Arg Ile Gly Glu65 70 75 80Gln Val Leu Gly Pro Gly Leu Arg Asp Leu Ala Ala Arg His Arg Ser 85 90 95Val Gly Glu Val Arg Gly Leu Gly Val Phe Trp Ala Gly Ser Asp Pro 100 105 110Glu Arg Ala Gly Leu Arg Val Glu Val Leu Gly Ala Gln Cys Arg Arg 115 120 125Arg Asp Val Val Gly Ala Gly Asp Ala Ala Ala Val Gly Val Leu Gly 130 135 140Pro Gln Arg Gln His Arg Ala Arg Ala Asp Gly Ser Asp Arg Gln Ala145 150 155 160Ser Arg Thr Val Ser Gly Val Pro Val Glu Ser Asn Val Leu Ser Ala 165 170 175Gly Ile Arg Cys Arg Thr Pro Thr Thr Arg Ala Val Ala Ile Cys Leu 180 185 190Ala Thr Leu Ala Ser Arg Gly Val Val Ala Pro Gln Pro Ala Gly Asp 195 200 205Val Ala Arg Ala Ala Ala Ala Gly Ser Pro Trp Pro Val Arg Ser Val 210 215 220Ala Arg Pro Val Ala Val Leu Arg Thr Gly Pro Pro Pro Arg Arg Pro225 230 235 240Ser Asp Thr Gly Ser Asp Gln Leu Gly Glu Pro Gly Ala Gln Gln Arg 245 250 255Gln Arg Gly Lys His Arg Asp Arg Arg Asp Val Pro Ala Gln Gln Arg 260 265 270Pro Ala Val His Pro Ala Gly Pro Gly Pro Ala Asp Arg Val Gly Val 275 280 285Asp Pro Gly Arg His Arg Arg Ala Arg Gly Gln His Gln Pro Arg Asp 290 295 300Gly Ser Ile Ser Ser Ala Leu Val Ala Ser Pro Pro Arg Ala Ala Ser305 310 315 320Ser Ala Pro Ala Ser Ile Gly Leu Gly Pro Ser Gly Gln His Thr Ser 325 330 335Ile His Pro Arg Ser Ser Asn Gly Ser Pro Thr Val His Ile Ser Gln 340 345 350Ser Met Asn Ala Ala Ser Ser Gly Thr Ser Arg Arg Ser Ser Thr Leu 355 360 365Phe Arg Trp Gln Ser Pro Cys Met Ile Pro Gly Ser Ala Ser Ser Gly 370 375 380Leu Arg Glu Ser Ser Gln Ser Ala Ser Thr Cys Thr Asp Gly Asn Asp385 390 395 400Ser Gly Ala Gly Ser Ile Thr Gln Val Gly Arg Pro Ala Val Leu Phe 405 410 415Ala Pro Glu Gln Arg Cys Arg Arg Arg Ala Asp Gln Arg Ser Cys Arg 420 425 430Gln Ile His Pro Gly Gly Gly Arg His Val Gln Ile Val Ala Ser Ala 435 440 445Arg Gly Thr Val Glu Ile Gly Ser Ile Ala Arg Leu Cys Gly Lys Asp 450 455 460Glu Ala Val Ala Ala Leu His Tyr Val Ala Pro Val Gly Glu Lys Gln465 470 475 480Asp Tyr Ile Asp Arg Ala Leu Arg Asn Ile Gly Pro Tyr Leu Pro Ala 485 490 495Glu Val Pro Ala Leu Val Gly Ser Ile Ala Ala Thr Gly Pro Val Pro 500 505 510Gly Thr Ala Trp Ile Val Arg Gln Tyr Pro Lys Leu Leu Arg Ala Lys 515 520 525Ala Asn Trp Glu Asp Thr Trp Thr Phe Pro Ser Ile Glu Glu Lys His 530 535 540Arg Pro Arg Gly Ser Val Ala Gly Pro Val Phe Arg Val Asn Leu Gly545 550 555 560Arg Ala Ile Pro Ser Arg Ala Ala Arg Ala Ala Glu Ile His Gly Ser 565 570 575His His His His His His 580 80 582 PRT Artificial Sequence Made in a lab 80Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu 1 5 10 15Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Phe Pro Thr Ile Pro Gly 20 25 30Ser Ile Tyr Ser Thr Phe Ala Asp Arg Ala Tyr Pro Gly Gly Leu Thr 35 40 45Tyr Ser Gly His Pro Leu Ala Thr Ala Cys Ala Val Ala Thr Ile Asn 50 55 60Ala Met Glu Asp Glu Gly Met Val Ala Asn Ala Ala Arg Ile Gly Glu65 70 75 80Gln Val Leu Gly Pro Gly Leu Arg Asp Leu Ala Ala Arg His Arg Ser 85 90 95Val Gly Glu Val Arg Gly Leu Gly Val Phe Trp Ala Gly Ser Ile Ser 100 105 110Ser Ala Leu Val Ala Ser Pro Pro Arg Ala Ala Ser Ser Ala Pro Ala 115 120 125Ser Ile Gly Leu Gly Pro Ser Gly Gln His Thr Ser Ile His Pro Arg 130 135 140Ser Ser Asn Gly Ser Pro Thr Val His Ile Ser Gln Ser Met Asn Ala145 150 155 160Ala Ser Ser Gly Thr Ser Arg Arg Ser Ser Thr Leu Phe Arg Trp Gln 165 170 175Ser Pro Cys Met Ile Pro Gly Ser Ala Ser Ser Gly Leu Arg Glu Ser 180 185 190Ser Gln Ser Ala Ser Thr Cys Thr Asp Gly Asn Asp Ser Gly Ala Gly 195 200 205Ser Asp Arg Gln Ala Ser Arg Thr Val Ser Gly Val Pro Val Glu Ser 210 215 220Asn Val Leu Ser Ala Gly Ile Arg Cys Arg Thr Pro Thr Thr Arg Ala225 230 235 240Val Ala Ile Cys Leu Ala Thr Leu Ala Ser Arg Gly Val Val Ala Pro 245 250 255Gln Pro Ala Gly Asp Val Ala Arg Ala Ala Ala Ala Gly Ser Pro Trp 260 265 270Pro Val Arg Ser Val Ala Arg Pro Val Ala Val Leu Arg Thr Gly Pro 275 280 285Pro Pro Arg Arg Pro Ser Asp Thr Gly Ser Asp Gln Leu Gly Glu Pro 290 295 300Gly Ala Gln Gln Arg Gln Arg Gly Lys His Arg Asp Arg Arg Asp Val305 310 315 320Pro Ala Gln Gln Arg Pro Ala Val His Pro Ala Gly Pro Gly Pro Ala 325 330 335Asp Arg Val Gly Val Asp Pro Gly Arg His Arg Arg Ala Arg Gly Gln 340 345 350His Gln Pro Arg Asp Gly Ser Ile Thr Gln Val Gly Arg Pro Ala Val 355 360 365Leu Phe Ala Pro Glu Gln Arg Cys Arg Arg Arg Ala Asp Gln Arg Ser 370 375 380Cys Arg Gln Ile His Pro Gly Gly Gly Arg His Val Gln Ile Val Ala385 390 395 400Ser Ala Arg Gly Thr Val Glu Ile Gly Ser Ile Ala Arg Leu Cys Gly 405 410 415Lys Asp Glu Ala Val Ala Ala Leu His Tyr Val Ala Pro Val Gly Glu 420 425 430Lys Gln Asp Tyr Ile Asp Arg Ala Leu Arg Asn Ile Gly Pro Tyr Leu 435 440 445Pro Ala Glu Val Pro Ala Leu Val Gly Ser Asp Pro Glu Arg Ala Gly 450 455 460Leu Arg Val Glu Val Leu Gly Ala Gln Cys Arg Arg Arg Asp Val Val465 470 475 480Gly Ala Gly Asp Ala Ala Ala Val Gly Val Leu Gly Pro Gln Arg Gln 485 490 495His Arg Ala Arg Ala Asp Gly Ser Ile Ala Ala Thr Gly Pro Val Pro 500 505 510Gly Thr Ala Trp Ile Val Arg Gln Tyr Pro Lys Leu Leu Arg Ala Lys 515 520 525Ala Asn Trp Glu Asp Thr Trp Thr Phe Pro Ser Ile Glu Glu Lys His 530 535 540Arg Pro Arg Gly Ser Val Ala Gly Pro Val Phe Arg Val Asn Leu Gly545 550 555 560Arg Ala Ile Pro Ser Arg Ala Ala Arg Ala Ala Glu Ile His Gly Ser 565 570 575His His His His His His 580 81 582 PRT Artificial Sequence Made in a lab 81Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu 1 5 10 15Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Phe Pro Thr Ile Pro Gly 20 25 30Ser Ile Tyr Ser Thr Phe Ala Asp Arg Ala Tyr Pro Gly Gly Leu Thr 35 40 45Tyr Ser Gly His Pro Leu Ala Thr Ala Cys Ala Val Ala Thr Ile Asn 50 55 60Ala Met Glu Asp Glu Gly Met Val Ala Asn Ala Ala Arg Ile Gly Glu65 70 75 80Gln Val Leu Gly Pro Gly Leu Arg Asp Leu Ala Ala Arg His Arg Ser 85 90 95Val Gly Glu Val Arg Gly Leu Gly Val Phe Trp Ala Gly Ser Asp Pro 100 105 110Glu Arg Ala Gly Leu Arg Val Glu Val Leu Gly Ala Gln Cys Arg Arg 115 120 125Arg Asp Val Val Gly Ala Gly Asp Ala Ala Ala Val Gly Val Leu Gly 130 135 140Pro Gln Arg Gln His Arg Ala Arg Ala Asp Gly Ser Ile Ser Ser Ala145 150 155 160Leu Val Ala Ser Pro Pro Arg Ala Ala Ser Ser Ala Pro Ala Ser Ile 165 170 175Gly Leu Gly Pro Ser Gly Gln His Thr Ser Ile His Pro Arg Ser Ser 180 185 190Asn Gly Ser Pro Thr Val His Ile Ser Gln Ser Met Asn Ala Ala Ser 195 200 205Ser Gly Thr Ser Arg Arg Ser Ser Thr Leu Phe Arg Trp Gln Ser Pro 210 215 220Cys Met Ile Pro Gly Ser Ala Ser Ser Gly Leu Arg Glu Ser Ser Gln225 230 235 240Ser Ala Ser Thr Cys Thr Asp Gly Asn Asp Ser Gly Ala Gly Ser Asp 245 250 255Gln Leu Gly Glu Pro Gly Ala Gln Gln Arg Gln Arg Gly Lys His Arg 260 265 270Asp Arg Arg Asp Val Pro Ala Gln Gln Arg Pro Ala Val His Pro Ala 275 280 285Gly Pro Gly Pro Ala Asp Arg Val Gly Val Asp Pro Gly Arg His Arg 290 295 300Arg Ala Arg Gly Gln His Gln Pro Arg Asp Gly Ser Asp Arg Gln Ala305 310 315 320Ser Arg Thr Val Ser Gly Val Pro Val Glu Ser Asn Val Leu Ser Ala 325 330 335Gly Ile Arg Cys Arg Thr Pro Thr Thr Arg Ala Val Ala Ile Cys Leu 340 345 350Ala Thr Leu Ala Ser Arg Gly Val Val Ala Pro Gln Pro Ala Gly Asp 355 360 365Val Ala Arg Ala Ala Ala Ala Gly Ser Pro Trp Pro Val Arg Ser Val 370 375 380Ala Arg Pro Val Ala Val Leu Arg Thr Gly Pro Pro Pro Arg Arg Pro385 390 395 400Ser Asp Thr Gly Ser Ile Thr Gln Val Gly Arg Pro Ala Val Leu Phe 405 410 415Ala Pro Glu Gln Arg Cys Arg Arg Arg Ala Asp Gln Arg Ser Cys Arg 420 425 430Gln Ile His Pro Gly Gly Gly Arg His Val Gln Ile Val Ala Ser Ala 435 440 445Arg Gly Thr Val Glu Ile Gly Ser Ile Ala Arg Leu Cys Gly Lys Asp 450 455 460Glu Ala Val Ala Ala Leu His Tyr Val Ala Pro Val Gly Glu Lys Gln465 470 475 480Asp Tyr Ile Asp Arg Ala Leu Arg Asn Ile Gly Pro Tyr Leu Pro Ala 485 490 495Glu Val Pro Ala Leu Val Gly Ser Ile Ala Ala Thr Gly Pro Val Pro 500 505 510Gly Thr Ala Trp Ile Val Arg Gln Tyr Pro Lys Leu Leu Arg Ala Lys 515 520 525Ala Asn Trp Glu Asp Thr Trp Thr Phe Pro Ser Ile Glu Glu Lys His 530 535 540Arg Pro Arg Gly Ser Val Ala Gly Pro Val Phe Arg Val Asn Leu Gly545 550 555 560Arg Ala Ile Pro Ser Arg Ala Ala Arg Ala Ala Glu Ile His Gly Ser 565 570 575His His His His His His 580

Claims

1. An isolated polynucleotide comprising SEQ ID NO: 15.

2. A DNA construct comprising at least one polynucleotide according to claim 1.

3. The DNA construct of claim 2, wherein the construct comprises a sequence selected from the group consisting of SEQ ID NO: 56 and 57.

4. The DNA construct of claim 2, wherein the construct comprises SEQ ID NO:58.

5. A host cell transformed with a DNA construct according to claim 2.

6. A host cell transformed with a DNA construct of claim 3.

7. A host cell transformed with a DNA construct according to claim 4.

8. An isolated polynucleotide comprising a sequence selected from the group consisting of:(a) sequences having at least 75% identical residues to SEQ ID NO: 15; (b) sequences having at least 90% identical residues to SEQ ID NO: 15; and (c) complements of SEQ ID NO: 15, wherein the polynucleotide possesses an ability to stimulate cytokine production.

9. A DNA construct comprising at least one polynucleotide according to claim 8.